

Hijacking of transcriptional condensates by endogenous retroviruses

Vahid Asimi

Max Planck Institute for Molecular Genetics

Sara Hetzel

Max Planck

Abhishek Sampath Kumar

MPIMG

Henri Niskanen

MPIMG

Christina Riemenschneider

MPIMG

Julian Naderi

MPIMG

Nina Fasching

Institute of Molecular Biotechnology (IMBA)

Niko Popitsch

Institute of Molecular Biotechnology (IMBA)

Helene Kretzmer

Max Planck Institute for Molecular Genetics

Zachary Smith

Harvard University

Maria Walther

Max Planck Institute for Molecular Genetics

David Meierhofer

Max Planck Institute for Molecular Genetics

Lars Wittler

Max Planck Institute for Molecular Genetics

René Buschow

MPIMG <https://orcid.org/0000-0002-9800-2578>

Bernd Timmermann

Sequencing Core Facility, Max Planck Institute for Molecular Genetics

Stefan Ameres

Institute of Molecular Biotechnology (IMBA)

Alexander Meissner

Max Planck Institute for Molecular Genetics <https://orcid.org/0000-0001-8646-7469>

Denes Hnisz (✉ hnisz@molgen.mpg.de)

Max Planck <https://orcid.org/0000-0002-6256-1693>

Article

Keywords: Endogenous retroviruses, retrotransposons, transcriptional condensates

Posted Date: September 15th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-802409/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Genetics on July 21st, 2022. See the published version at <https://doi.org/10.1038/s41588-022-01132-w>.

1 Hijacking of transcriptional condensates by endogenous retroviruses

2

3 Vahid Asimi^{1†}, Sara Hetzel^{1†}, Abhishek Sampath Kumar^{1†}, Henri Niskanen^{1†}, Christina
4 Riemenschneider^{1,2†}, Julian Naderi¹, Nina Fasching³, Niko Popitsch³, Helene Kretzmer¹,
5 Zachary D. Smith^{4,5}, Maria Walther¹, David Meierhofer⁶, Lars Wittler⁷, Rene Buschow⁸, Bernd
6 Timmermann⁹, Stefan L. Ameres^{3,10}, Alexander Meissner^{1,4,5}, Denes Hnisz^{1*}

7

8

9 ¹ Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin,
10 Germany

11 ² Institute of Biotechnology, Technische Universität Berlin, Berlin, Germany

12 ³ Institute of Molecular Biotechnology (IMBA), Vienna BioCenter (VBC), Vienna, Austria.

13 ⁴ Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

14 ⁵ Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge,
15 Massachusetts, USA

16 ⁶ Max Planck Institute for Molecular Genetics, Mass Spectrometry Facility, Berlin, Germany

17 ⁷ Department of Developmental Genetics, Max Planck Institute for Molecular Genetics, Berlin,
18 Germany

19 ⁸ Microscopy Core Facility, Max Planck Institute for Molecular Genetics, Berlin, Germany

20 ⁹ Sequencing Core Facility, Max Planck Institute for Molecular Genetics, Berlin, Germany

21 ¹⁰ Department of Biochemistry and Cell Biology, Max Perutz Labs, University of Vienna,
22 Vienna BioCenter (VBC), Vienna, Austria

23 † these authors contributed equally

24

25

26 * Correspondence: hnisz@molgen.mpg.de

27 **Endogenous retroviruses (ERVs) comprise ~10% of mammalian genomes, and ERVs are**
28 **repressed by multiple cellular mechanisms including heterochromatin, DNA methylation,**
29 **and methylation of their RNA transcripts¹⁻¹³. Although the vast majority of ERVs in**
30 **mammals are incapable of retrotransposition, ERV de-repression during early**
31 **development is associated with embryonic lethality¹⁴⁻¹⁶, suggesting that ERV transcription**
32 **or RNA transcripts may underlie essentiality of ERV repression. Here we report that rapid**
33 **and selective degradation of the TRIM28 heterochromatin adapter protein in murine**
34 **embryonic stem cells triggers dissociation of transcriptional condensates from loci encoding**
35 **super-enhancer -driven pluripotency genes, and association of transcriptional condensates**
36 **with transcribed ERV loci. Knockdown of ERV RNA or forced expression of super-**
37 **enhancer -enriched transcription factors rescued condensate localization at super-**
38 **enhancers in TRIM28-degraded cells. In a biochemical reconstitution system, ERV RNA**
39 **facilitated phase separation of RNA Polymerase II, and partitioning of NFY and Mediator**
40 **into heterotypic droplets, suggesting a mechanistic basis for the association of**
41 **transcriptional condensates with ERVs. Using a zygotic perturbation platform, we found**
42 **that timing and amount of ERV transcription correlate with the onset of lethality, and that**
43 **loss of TRIM28 leads to specific depletion of pluripotent lineages in mouse embryos. We**
44 **propose that retrotransposons contribute to the genomic distribution of nuclear**
45 **condensates, and that coding and non-coding nascent RNAs may facilitate “hijacking” of**
46 **transcriptional condensates in various developmental and disease contexts.**

47

48 Heterochromatin plays essential roles in repressing retrotransposons such as endogenous
49 retroviruses (ERVs) during embryonic development¹⁻⁶. One of the best studied repressive
50 pathways involves the TRIM28 co-repressor recruited by KRAB-ZFP transcription factors to
51 ERVs in pluripotent embryonic stem cells (ESCs), where it recruits the histone H3K9
52 methyltransferase SETDB1 and HP1 α that establish a repressive chromatin environment^{7,9,17-20}
53 (Fig. 1a-b, Extended Data Fig. 1a-j). In contrast, heterochromatin components typically do not
54 occupy transcription-factor bound enhancers that drive cell-specific transcriptional programs
55 (Fig. 1a-b, Extended Data Fig. 1a-j)^{7,21,22}. ERV de-repression is associated with lethality at
56 various embryonic stages and in pluripotent stem cells deficient for the TRIM28-HP1 α pathway
57⁷⁻¹⁰, even though the vast majority of ERVs in mice and humans have lost their ability to

58 retrotranspose¹⁻⁶, and deletion of entire clusters of KRAB-ZFP factors does not lead to elevated
59 transposition rates in mice¹⁶. Previous studies suggested that de-repressed ERVs can act as
60 enhancers and alternative promoters of cellular genes^{1,23-25}, but why ERV de-repression may be
61 lethal in early embryos and pluripotent cells is a mystery.

62
63 Resolving the direct consequences of ERV de-repression has in part been impeded by limitations
64 of classic gene disruption strategies and essentiality of the TRIM28-HP1 α pathway in embryonic
65 cells⁷⁻¹⁰. Therefore, we first generated a murine embryonic stem cell (ESC) line that encodes
66 degradation-sensitive TRIM28-FKBP alleles using the dTAG technology (Fig. 1c, Extended
67 Data Fig. 2a-b)²⁶. Endogenously tagged TRIM28 experienced reversible, ligand-dependent
68 proteolysis with near-complete degradation after 6h exposure to the dTAG-13 ligand (Fig. 1d,
69 Extended Data Fig. 2b). Quantitative mass-spectrometry confirmed that TRIM28 degradation
70 was highly selective up to 24h of dTAG-13 treatment (Extended Data Fig. 2c). Of note, short
71 term (up to 24h) TRIM28 degradation did not substantially alter the protein levels of
72 pluripotency markers (e.g. OCT4, SOX2, SSEA-1) (Fig. 1d, Extended Data Fig. 2d-e) suggesting
73 that acute TRIM28 degradation did not considerably alter the pluripotent state.

74
75 To monitor changes in transcriptional activity upon acute TRIM28-degradation, we used TT-
76 SLAM-Seq, a recently developed high-sensitivity genome-wide nascent transcription readout²⁷.
77 TT-SLAM-Seq combines metabolic labeling and chemical nucleoside conversion (SLAM-Seq)
78²⁸ with selective enrichment of newly synthesized RNA (TT-Seq)²⁹ to detect nascent RNA
79 transcription with high temporal resolution and sensitivity (Extended Data Fig. 3a-c). Consistent
80 with previous reports^{7,24}, we observed de-repression of major classes of ERVs, including
81 intracisternal A-type particles (IAPs), MMERVK10s and MMERVK9s in TRIM28-degraded
82 ESCs (Fig. 1e, Extended Data Fig. 4a-f), and loss of H3K9me3 at these sites (Extended Data Fig.
83 4g). De-repression of ERVs was also confirmed with extended TRIM28-degradation for 96h and
84 RNA-Seq (Fig. 1e, Extended Data Fig. 4a-e). The TT-SLAM-Seq data revealed ~300 genes
85 whose transcription was significantly induced, and ~300 genes whose transcription was
86 significantly reduced upon 24h of TRIM28 degradation (>2-fold, FDR<0.05) (Fig. 1f-g). The
87 downregulated genes were enriched for super-enhancer-associated pluripotency genes (NES=-
88 1.6, p<10⁻³) (Fig. 1f-g, Extended Data Fig. 5a-d). Downregulation of these genes was associated

89 with the reduction of nascent transcription at the super-enhancers, that tended to precede the
90 reduction of transcription at the super-enhancer -driven gene (Fig. 1f, 1h, Extended Data Fig. 5a-
91 c). These results were unexpected, as TRIM28 binds to ERVs in the genome of ESCs and is not
92 bound at enhancers or super-enhancers (Fig. 1b, Extended Data Fig. 1i-j), and because previous
93 studies using genetic disruption and long term cultures (96 hours) reported 8-times more
94 upregulated than downregulated genes in TRIM28 KO ESCs²⁴. These data reveal the direct
95 transcriptional response to the loss of TRIM28, and suggest that acute TRIM28 degradation leads
96 to reduction of super-enhancer transcription in ESCs.

97
98 Components of the transcription machinery, e.g. RNA Polymerase II (RNAPII) and the Mediator
99 co-activator form biomolecular condensates that associate with super-enhancers in ESCs³⁰⁻³³,
100 and the presence of RNAPII condensates at genomic sites correlates with elevated transcriptional
101 activity³². We thus hypothesized that reduction of super-enhancer transcription in TRIM28-
102 degraded ESCs may be caused by dissociation of transcriptional condensates from super-
103 enhancer loci. To test this idea, we visualized the genomic region containing the super-enhancer
104 at the *MiR290-295* locus using nascent RNA-FISH, and transcriptional condensates using
105 immunofluorescence against RNAPII. RNAPII puncta consistently co-localized with the
106 *MiR290-295* locus in control ESCs, and the co-localization was diminished after 24h of TRIM28
107 degradation (Fig. 1i, Extended Data Fig. 6a), while the overall level of RNAPII did not change
108 (Extended Data Fig. 6b). These data indicate that transcriptional condensates less frequently
109 associate with the *MiR290-295* super-enhancer locus in TRIM28-degraded ESCs.

110
111 To investigate whether transcriptional condensates co-localize with de-repressed ERVs, we
112 visualized IAP ERV loci with RNA-FISH. Nuclear *IAP* foci became progressively apparent after
113 24-48h of TRIM28-degradation (Fig. 2a, Extended Data Fig. 7a), and some nuclear *IAP* foci co-
114 localized with RNAPII puncta visualized with IF [Mean Mander's co-localization coefficient
115 (MCC): 0.1, n=98 cells] (Fig. 2a, Extended Data Fig. 7a). Co-localization of *IAP* foci was
116 similarly observed with Mediator puncta visualized with IF using antibodies against the MED1
117 and MED23 Mediator subunits (Fig. 2b, Extended Data Fig. 7b), and with the NFY transcription
118 factor (TF), whose motif is significantly enriched in the Long Terminal Repeat (LTR) of IAPs
119 (Fig. 2c, Extended Data Fig. 8a). Consistent with the co-localization of transcriptional

120 condensates with *IAP* foci and their loss of co-localization with super-enhancers, the occupancy
121 of RNAPII, Mediator and the transcription-associated H3K27Ac chromatin footprint increased at
122 various ERV families already after 24h TRIM28-degradation, while their occupancy was
123 reduced at super-enhancers (Fig. 2d, Extended Data Fig. 9a-b).

124

125 As newly formed transcriptional condensates could influence their genomic environment, we
126 explored the possibility that transcriptional condensates associating with ERVs may incorporate
127 ERV-proximal genes. To this end, we visualized the *Cthrc1* locus using nascent RNA-FISH, as
128 *Cthrc1* was among the most upregulated genes in the TT-SLAM-Seq data after 24h of TRIM28-
129 degradation, and is located within 100kb of three ERVs (Fig. 2e). We found that the *Cthrc1*
130 locus co-localized with RNAPII and NFY puncta in TRIM28-degraded ESCs (Fig. 2f-g,
131 Extended Data Fig. 8b-c), but not with puncta of a control TF NRF1 (Extended Data Fig. 8d).
132 Transient (30min) treatment of the cells with 1.5% 1-6 hexanediol (1-6 HD), a short chain
133 aliphatic alcohol that dissolves various biomolecular condensates including RNAPII condensates
134 ³² (Extended Data Fig. 7c-d), reduced the level of *Cthrc1* nascent RNA (2-fold, $p < 0.05$, t-test) in
135 TRIM28-degraded cells, indicating that RNAPII condensates contribute to the upregulation of
136 this gene (Extended Data Fig. 7e). We then used CRISPR/Cas9 to delete the three ERVs at the
137 *Cthrc1* locus, and found that in the absence of the three ERVs, *Cthrc1* was not induced upon
138 TRIM28-degradation (Extended Data Fig. 7f-g). To further probe contacts between de-repressed
139 ERVs and genes, we performed in situ Hi-C in control and TRIM28-degraded ESCs. 24h of
140 TRIM28 degradation did not lead to major genome-wide changes in chromatin contacts
141 (Extended Data Fig. 10a-b), but did lead to a shift of the most-induced ERV taxa from the
142 inactive “B” to the active “A” compartment (Fig. 2h, Extended Data Fig. 10c), and an increase of
143 the contact frequency between ERVs and transcribed genes (Fig. 2i, Extended Data Fig. 10b,
144 10d). These results demonstrate that transcriptional condensates may incorporate genes and de-
145 repressed ERVs.

146

147 RNA is a key component of numerous biomolecular condensates ³⁴, and nascent RNA can
148 enhance phase separation of transcriptional regulatory proteins ³⁵. Therefore, we hypothesized
149 that RNA produced at ERV loci may contribute to the genomic localization of RNAPII-
150 containing condensates. To test this model, we knocked-down various ERV RNAs in TRIM28-

151 degraded cells. Expression of shRNAs targeting the four most-induced ERV families (IAPs,
152 MMERVK10s, MMERVK9s, MMEtNs) partially rescued the downregulation of super-
153 enhancers and their associated genes after 24h of TRIM28 degradation while knocking down
154 IAPs alone did not (Extended Data Fig. 11a-d). However, expression of the shRNAs for 24h
155 before inducing TRIM28 degradation (for 24h) almost entirely rescued ERV transcript levels
156 (Fig. 3a-b, Extended Data Fig. 11e-f), the appearance of IAP RNA FISH foci (Extended Data
157 Fig. 11g), transcription at super-enhancers and their associated genes (Fig. 3b, Extended Data
158 Fig. 11e-f), and the association of RNAPII-condensates at the *Mir290-295* super-enhancer locus
159 (Fig. 3c).

160
161 To further dissect the relationship between ERV RNA and transcriptional condensates, we
162 performed in vitro reconstitution experiments. We purified recombinant, mCherry-tagged C-
163 terminal domain (CTD) of RNAPII, which was previously shown to form condensates in vitro
164 ^{30,33}, and mixed it with fluorescein-labeled in vitro-transcribed IAP RNA fragments. The IAP
165 RNA fragments facilitated RNAPII CTD droplet formation in a dose-dependent manner (Fig. 3d-
166 3e, Extended Data Fig. 12a), and the IAP RNA was enriched within RNAPII CTD droplets in a
167 dose-dependent manner (Fig. 3d, f). IAP RNA also facilitated condensation of the intrinsically
168 disordered region (IDR) of the MED1 Mediator subunit Extended Data Fig. 12b-f), a frequently
169 used in vitro model of Mediator ^{31,33,36}. Furthermore, IAP RNA enhanced droplet formation of
170 purified recombinant HP1 α (an in vitro model of heterochromatin ³⁷), but the optimal
171 concentration of the RNA was about 5-fold lower for HP1 α than MED1 IDR in this in vitro
172 system (Fig. 3g, Extended Data Fig. 13a-b). As expected, various other RNAs e.g. super-
173 enhancer RNA ³⁵ and RNA from major satellite repeats ³⁸ also enhanced droplet formation of
174 MED1 IDR and HP1 α in vitro, but the difference in the optimal RNA concentration stayed
175 consistently about 5-fold (Extended Data Fig. 13a-b). Moreover, IAP RNA fragments facilitated
176 partitioning of both the MED1 IDR and NFYC IDR into IAP-RNA -containing heterotypic
177 droplets (Fig. 3h-i, Extended Data Fig 12h-j). These results indicate that IAP RNA can enhance
178 droplet formation of key transcriptional regulatory proteins, and suggest a mechanistic basis for
179 the difference of the effect of RNA on heterochromatin and transcriptional condensates.
180

181 RNAPII and Mediator-containing condensates are thought to be anchored at super-enhancers by
182 transcription factors (TFs) that are enriched at these sites ³⁶. One would thus expect that the loss
183 of transcriptional condensates at super-enhancers in TRIM28-degraded cells is rescued by
184 overexpression of super-enhancer –enriched transcription factors. To test this idea, we generated
185 degradation-sensitive TRIM28-FKBP alleles in an induced pluripotent stem cell (iPSC) line that
186 contains integrated transgenes encoding OCT4, SOX2, KLF4 and MYC under a doxycycline-
187 inducible promoter (Fig. 4a-b, Extended Data Fig. 14a-b) ³⁹. OCT4, SOX2 and KLF4 are highly
188 enriched at super-enhancers in ESCs ⁴⁰. TRIM28 degradation in the iPSCs led to the appearance
189 of IAP foci as revealed by IAP RNA-FISH (Fig. 4c-d). Overexpression of OCT4, SOX2, KLF4
190 and MYC significantly reduced the fraction of iPSCs containing IAP foci (Fig. 4c-d), and overall
191 *IAP* RNA level in the cell population (Fig. 4e). Furthermore, RNAPII puncta co-localized with
192 the *MiR290-295* super-enhancer locus more frequently in TRIM28-degraded cells that
193 overexpressed OCT4, SOX2, KLF4 and MYC (Fig. 4f) while the overall levels of RNAPII
194 subunits did not change (Extended Data Fig. 14c-d). OCT4, SOX2, KLF4 and MYC
195 overexpression also partially rescued the downregulation of the *MiR290-295* super-enhancer
196 RNA and *Pri-MiR290-295* transcript in TRIM28-degraded cells (Fig. 4g) and nascent transcript
197 levels at the *Klf4*, *Fgf4*, *Oct4* and *Mycn* super-enhancer loci (Extended Data Fig. 14e-h). These
198 results suggest that forced expression of super-enhancer –binding TFs prevents the loss of
199 transcriptional condensates at the *MiR290-295* super-enhancer locus in TRIM28-degraded cells.

200

201 De-repressed ERV loci appear to compete for transcriptional condensates with super-enhancers,
202 in part through producing RNA that facilitates condensation of transcriptional activators. To
203 directly probe this competition, we investigated whether simultaneously activated transcription at
204 repetitive loci (e.g. ERVs) could compromise transcription at super-enhancers. First, we
205 attempted to activate IAPs using CRISPRa ⁴¹, but targeting a dCas9-VP64 protein to IAPs with
206 several guide RNAs failed to produce meaningful transcription at those elements (not shown).
207 We then mimicked the effect of simultaneous ERV induction by generating three independent
208 mESC lines that contain different copy numbers of an integrated Piggyback transposon encoding
209 a Dox-inducible GFP transgene (Fig. 4h, Extended Data Fig 15a-c). Induction of the GFP
210 transgenes in cells that contain the highest copy number of the transposon lead to a significant
211 downregulation of super-enhancer transcription (Fig. 4i, Extended Data Fig 15d), and even

212 compromised *IAP* and *Cthrc1* induction in TRIM28-degraded cells (Fig 4i, Extended Data Fig.
213 15c). These results demonstrate that simultaneous activation of model transposon loci may
214 compromise super-enhancer transcription in mESCs.

215
216 The above results suggest that pluripotent stem cells fail to maintain transcription of super-
217 enhancer -driven pluripotency genes when ERV repression is compromised, and predict that the
218 amount of ERV products would correlate with the inability of embryos to maintain a pluripotent
219 compartment. To test this model in vivo, we used our recently developed zygotic perturbation
220 platform (Fig. 5a) ⁴². We generated zygotic deletion mutants of TRIM28, SETDB1, HP1 α and
221 other epigenetic regulators implicated in ERV repression, and assayed the timing and amount of
222 the GAG protein produced by IAPs (Fig. 5b-c). IAP GAG foci were detected in E3.5 blastocysts
223 of TRIM28, SETDB1 and KDM1A KO mutants, and these mutations were lethal at ~E6.5 in
224 embryos. In contrast, IAP GAG foci appeared ~3 days later in DNMT1 KO embryos (Fig. 5b-c),
225 and earlier appearance of IAP GAG foci correlated with the onset of embryonic lethality (Fig.
226 5c-d).

227
228 To probe which cell types are affected by the presence of IAP foci in blastocysts, we used
229 scRNA-Seq. We created a reference cell state map of an early mouse embryo spanning a window
230 of developmental stages (E5.5 to E7.0) that encompass the reported onset of lethality in TRIM28
231 knock-out mice (~E6.5) (Extended Data Fig. 16a-e) ⁷. We then generated TRIM28-deficient
232 embryos using Cas9/sgRNA delivery into zygotes, and mapped cell states using scRNA-Seq
233 (Fig. 5e, Extended Data Fig. 16f). qRT-PCR data confirmed that IAPs were upregulated in
234 TRIM28 KO embryos (Fig. 5f, Extended Data Fig. 16g). The E6.5 scRNA-Seq data revealed a
235 dramatic scarcity of epiblast cells normally derived from pluripotent cells of the inner cell mass
236 (ICM) (Fig. 5e), and an abundance of extraembryonic lineages (e.g. parietal endoderm) in
237 TRIM28 KO embryos (Fig.5e, Extended Data Fig. S17a-b). Immunofluorescence imaging
238 showed that the pluripotency factors NANOG, OCT4, SOX2 and KLF4 were already virtually
239 absent in the ICM of TRIM28 KO E3.5 blastocysts (Fig. 5g, Extended Data Fig. 18a-b), and the
240 inner part of the blastocysts was instead populated by cells expressing the endoderm marker
241 GATA6 (Fig. 5g). This phenotype is reminiscent of NANOG knockout embryos, in which the
242 pluripotent ICM is replaced by GATA6-expressing parietal endoderm cells (Fig. 5g) ⁴³. These

243 data are consistent with upregulation of endoderm markers observed in TRIM28-degraded ESCs
244 (Extended Data Fig. 19a-b). Overall the findings suggest that extended ERV de-repression
245 results in the loss of expression of pluripotency genes and consequent depletion of pluripotent
246 cells in early mouse embryos.

247
248 The results presented here support a model that ERV retrotransposons have the capacity to hijack
249 biomolecular condensates formed by key transcriptional regulatory proteins in pluripotent cells
250 (Fig. 5h). This model may help explain why thousands of retrotransposition-incapable ERVs are
251 repressed in mammals and how their reactivation could alter cellular fates in the absence of
252 retrotransposition^{7,9,14-16,23,44,45}. De-repressed ERVs appear to compete with super-enhancers for
253 transcriptional condensates in pluripotent cells, and this competition may explain why
254 simultaneous transcription of multiple ERV loci are associated with embryonic lethality.
255 Furthermore, recent studies reported that m6A methylation plays important roles in repressing
256 ERV transcripts¹¹⁻¹³, and the contribution of ERV RNA to the hijacking of transcriptional
257 condensates from super-enhancers may explain the in vivo role and importance of ERV RNA
258 modifications. Many nuclear non-coding RNAs are known to localize to the loci where they are
259 produced⁴⁶, but their functions are mysterious. We propose, that such RNAs – like ERV RNAs –
260 may contribute to the genomic distribution of nuclear condensates. Sets of ERVs are transcribed
261 in various disease contexts include leukemias⁴⁷ and neurological diseases⁴⁸⁻⁵¹; suggesting that
262 the ERV RNA produced in those contexts may contribute to the pathologies through altering
263 nuclear condensate homeostasis.

264

265

266

267 **Acknowledgments:**

268

269 We thank Tugce Aktas and Aydan Bulut-Karslioglu for comments on the manuscript, Charles
270 Haggerty for S2 cells, Georg Winter and Martin Jäger for sharing RNAPII antibody, Alessandra
271 Dall’Agnese and Eric Guo for advice on FISH-IF, Alexandra Mattei for help with IF, Shaon
272 Basu for helping with co-localization analysis, Sebastian Mackowiak for help with code,
273 Charlotte Althoff for help with Western blots, Beate Lukaszewska-McGreal for help with Mass-

274 spectrometry, Celine Hillgardt, Christin Franke and the MPIMG transgenic facility for help with
275 mouse work, and the MPIMG Sequencing core for sequencing. **Funding:** This work was funded
276 by the Max Planck Society, and partially supported by grants from the NIH (1P50HG006193 to
277 A.M.) and the Deutsche Forschungsgemeinschaft (DFG) Priority Program Grant HN 4/1-1 (to
278 D.H.); the Austrian Academy of Sciences and the European Research Council (ERC) under the
279 European Union’s Horizon 2020 research and innovation programme (ERC-CoG-866166,
280 RiboTrace) (to S.L.A.). H.N is supported by fellowships from the Emil Aaltonen Foundation and
281 Orion Research Foundation. **Author contributions:** Conceptualization: V.A., S.H., A.S.K.,
282 H.N., A.M., D.H.; Investigation: V.A., A.S.K., H.N., C.R., J.N., N.F., Z.D.S., B.T., L.W.;
283 Methodology: N.F., N.P., S.H., H.N.; Software: S.H., N.P.; Formal analysis: V.A., S.H., H.N.,
284 R.B.; Resources: S.L.A., A.M., D.H.; Data curation: S.H., Visualization: V.A., S.H., A.S.K.,
285 H.N., C.R., J.N., Writing: V.A., S.H., A.S.K., H.N., A.M., D.H.; Supervision: A.M., D.H.,
286 Project administration: D.H.; Funding acquisition: S.L.A., A.M., D.H. **Competing interests:**
287 S.L.A. is founder and advisor of QUANTRO Therapeutics GmbH. A patent related to SLAMseq
288 has been awarded to S.L.A. (EP3589748B1) and licensed to Lexogen GmbH. **Data and**
289 **materials availability:** All data is available in the supplementary materials. Sequence data were
290 deposited at GEO under the accession number GSE159468. Mass spectrometry data were
291 deposited at ProteomeXchange under the accession ID PDX021895. **Code availability:** All
292 custom code used in this study is available upon request.

293

294 Reviewer access to deposited data:

295 Go to <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159468>

296 Enter token upgxequwxzylhgx into the box

297

298 A UCSC track hub for reviewers:

299 http://ngs.molgen.mpg.de/ngsuploads/dept_meissner/Trim28_Submission.txt


300

301 <http://proteomecentral.proteomexchange.org/cgi/GetDataset>

302 Username: reviewer_pxd021895@ebi.ac.uk

303 Password: zbELCqWf

Figure 1



306
 307 **Figure 1. TRIM28 degradation leads to the reduction of super-enhancer transcription and**
 308 **loss of transcriptional condensates at super-enhancers in mESCs**

309 **a.** (top) Model of TRIM28/HP1 α pathway and its major regulators at endogenous retroviruses
310 (ERVs). KRAB-ZFP: KRAB-Zinc Finger Protein, TRIM28: Tripartite motif -containing protein
311 28, HP1 α : heterochromatin protein 1 α , IAP: intracisternal A-type particle. (bottom) Model of
312 enhancers. Enhancers are bound by transcription factors (TFs) that recruit the Mediator complex
313 and RNA Polymerase II (RNAPII).

314 **b.** Heatmap representation of ChIP-seq read densities of the indicated factors within a 2kb
315 window around full-length IAP ERVs and enhancers in mESC. The genomic elements (the
316 middle part of the plots) were length normalized. Enhancers in mESCs are bound by the OCT4,
317 SOX2, NANOG TFs, and are devoid of components of the TRIM28/HP1 α pathway that are
318 bound at IAP ERVs. Enhancers include the constituent enhancers of super-enhancers and typical
319 enhancers. Rpm: reads per million.

320 **c.** Scheme of the dTAG system to degrade TRIM28 in mESCs.

321 **d.** Western blot validation of the FKBP degron tag and its ability to degrade TRIM28. The
322 protein levels of the pluripotency factors OCT4 and SOX2 do not change.

323 **e.** TRIM28-degradation leads to de-repression of IAP ERVs. Displayed is fold change in read
324 density from three replicates of TT-SLAM-Seq and RNA-Seq data after the indicated duration of
325 dTAG-13 treatment, normalized to the level in DMSO control.


326 **f.** Acute reduction of transcription at the *Klf4* super-enhancer locus upon TRIM28-degradation.
327 Displayed are genome browser tracks of ChIP-Seq data (H3K27Ac, OCT4, SOX2, NANOG) in
328 control mESCs and TT-SLAM-Seq data upon 0h, 2h, 6h and 24h dTAG-13 treatment at the *Klf4*
329 locus. Co-ordinates are mm10 genome assembly co-ordinates.

330 **g.** Volcano plots displaying fold change of gene transcription (TT-SLAM-Seq data) upon dTAG-
331 13 treatment. The number of significantly de-regulated genes, and genes implicated in the
332 control of pluripotency are highlighted.

333 **h.** Reduced transcription at super-enhancers in TRIM28-degraded cells. The box plots show log₂
334 fold change in transcription (TT-SLAM-Seq read density) at super-enhancers and typical
335 enhancers upon dTAG-13 treatment normalized to untreated control mESCs. P values are from
336 two tailed, one sample t tests. *****: P<10⁻⁴, ***: P<10⁻³, *: P<0.05.

337 **i.** Co-localization between the nascent RNA of *MiR290-295* and RNAPII puncta in mESCs. The
338 co-localization is lost upon TRIM28-degradation. Displayed are separate images of individual z-
339 slices (same z) of the RNA-FISH and IF signal, and an image of the merged channels. The nuclear
340 periphery determined by DAPI staining (not shown) is highlighted as a white contour. Also shown
341 are averaged signal of either RNA FISH or RNAPII IF centered on the *MiR290-295* FISH foci or
342 randomly selected positions. Scale bars: 2.5 μ m.

Figure 2



343

344

345 **Figure 2. De-repressed IAPs form nuclear foci that associate with RNAPII condensates,**
 346 **and incorporate nearby genes**

347 **a-c.** Co-localization between the *IAP* RNA and (a) RNAPII puncta (b) Mediator puncta and (c)
 348 NFYA puncta in TRIM28-degraded mESCs. Displayed are separate images of individual z-slices
 349 (same z) of the RNA-FISH and IF signal, and an image of the merged channels. The nuclear

350 periphery determined by DAPI staining (not shown) is highlighted as a white contour. The zoom
351 column displays the region of the images highlighted in a yellow box zoomed in for greater
352 detail. Scale bars: 2.5 μ m.

353 **d.** Elevated RNAPII and Mediator occupancy at various ERV classes in TRIM28-degraded
354 ESCs. Displayed are meta representations of RNAPII ChIP-RX read densities at IAP, MMERVK
355 and MMETn ERVs in control (DMSO) and dTAG-13 (24h) treated mESCs. The mean read
356 densities are displayed +/-2kb around the indicated elements. The genomic elements (the middle
357 part of the meta plot) were length normalized.


358 **e.** Genome browser tracks at the *Cthrc1* locus. The *Cthrc1* gene is surrounded by three ERVs
359 that lose H3K9me3 signal and gain occupancy of transcription-associated marks upon TRIM28-
360 degradation. Note the independent transcription initiation events at *Cthrc1* and MMETn, ruling
361 out that MMETn acts as an alternative *Cthrc1* promoter. Rpm: reads per million. Co-ordinates
362 are mm10 genome assembly co-ordinates.

363 **f-g.** Co-localization between the nascent RNA of *Cthrc1* and **(f)** RNAPII puncta and **(g)** NFY
364 puncta in TRIM28-degraded mESCs. Displayed are separate images of individual z-slices (same
365 z) of the RNA-FISH and IF signal, and an image of the merged channels. The nuclear periphery
366 determined by DAPI staining (not shown) is highlighted as a white contour. Also shown are
367 averaged signal of either RNA FISH or IF centered on the *Cthrc1* FISH foci or randomly
368 selected positions. Scale bars: 2.5 μ m.

369 **h.** Principal component (PC) plot of Hi-C interactions at an ERV-rich locus on chromosome 12.

370 **i.** Pile-up analysis of contacts between IAPs, MERVKs, MMETns and transcribed genes in wild
371 type and TRIM28-degraded mESCs.

Figure 3



372

373

374 **Figure 3. Contributions of IAP RNA to condensate localization in vivo and condensate**
 375 **formation in vitro**

376 **a.** Schematic model of the ERV shRNA knockdown experiments

377 **b.** Rescue of *Mir290-295* super-enhancer and primary transcript levels upon ERV RNA-

378 knockdown in TRIM28-degraded cells. The bar plots show qRT-PCR data as fold change

379 normalized to the DMSO treatment control. P values are from two-tailed t tests. ****: $P < 10^{-4}$,

380 ***: $P < 10^{-3}$, **: $P < 10^{-2}$.

381 **c.** Co-localization between the nascent RNA of *Mir290-295* and RNAPII puncta in TRIM28-

382 degraded mESCs upon ERV RNA-knockdown. Displayed are separate images of individual z-

383 slices (same z) of the RNA-FISH and IF signal, and an image of the merged channels. The

384 nuclear periphery determined by DAPI staining (not shown) is highlighted as a white contour.

385 Also shown are averaged signal of either RNA FISH or RNAPII IF centered on the *Mir290-295*

386 FISH foci or randomly selected positions. Scale bars: 2.5 μ m.

387 **d.** *IAP* RNA is enriched within RNAPII CTD droplets. Displayed are representative images of
388 mixtures of fluorescein-labeled *IAP* RNA and purified recombinant RNAPII CTD-mCherry in
389 droplet formation buffer. Scale bar: 5 μ m.

390 **e.** Partitioning ratio of RNAPII CTD-mCherry into droplets at the indicated *IAP* RNA
391 concentrations. Every dot represents a detected droplet.


392 **f.** Quantification of the enrichment of fluorescein-labeled *IAP* RNA in RNAPII CTD-mCherry
393 droplets.

394 **g.** Quantification of the partitioning of (top) MED1 IDR and (bottom) HPI α into droplets in the
395 presence of *IAP* RNA. Values are normalized against the partition ratio at no RNA added.
396 Corresponding images are found in Extended Data Fig. S13a.

397 **h.** The NFYC IDR forms heterotypic droplets with MED IDR in vitro, and *IAP* RNA facilitates
398 partitioning of both proteins into heterotypic droplets. Displayed are representative images of
399 droplet formation by purified NFYC IDR-mEGFP (1 μ M) and MED1 IDR-mCherry (5 μ M)
400 fusion proteins in the presence of in vitro transcribed Cy5-labelled *IAP* RNA fragment. Scale
401 bar: 5 μ m.

402 **i.** Partitioning ratio of NFYC IDR-mEGFP, MED1 IDR-mCherry and *IAP* RNA into droplets at
403 the indicated *IAP* RNA concentrations. Every dot represents a detected droplet. All pairwise P-
404 values < 2.2*10⁻¹⁶ (Welch's t-test).

Figure 4



405

406 **Figure 4. Super-enhancer -enriched transcription factors and repetitive RNA-producing**
 407 **loci compete for transcriptional activators**

408 **a.** Genotype of the iPSC line and scheme of the experimental setup. The iPSC cell line contains
 409 degradation-sensitive *Trim28-FKBP* alleles, and Doxycycline-inducible *Oct4*, *Sox2*, *Klf4*, *c-Myc*
 410 (OSKM) transgenes.

411 **b.** Western blot validation of the FKBP degron tag and OSKM ectopic expression in iPSCs.

412 **c.** OSKM ectopic expression reduces the number of IAP-expressing cells in the absence of
413 TRIM28. Displayed are representative images of IAP RNA FISH staining. The number and
414 percentage refer to cells with detectable IAP foci. Scale bars: 10 μ m, inset scale bars: 2 μ m.

415 **d.** Quantification of cells with detectable IAP foci (i.e. IAP+ cells) at the indicated treatment
416 regimes.

417 **e.** *IAP* RNA expression is reduced in TRIM28-degraded iPSCs that ectopically express OSKM
418 factors. The line plot shows qRT-PCR data of IAP RNA levels normalized to 0h of dTAG-13
419 treatment. *** $p < 10^{-3}$ two-tailed t test.


420 **f.** Co-localization between the nascent RNA of *MiR290-295* and RNAPII puncta in TRIM28-
421 degraded iPSCs that ectopically express OSKM factors. Displayed are separate images of
422 individual z-slices (same z) of the RNA-FISH and IF signal, and an image of the merged
423 channels. The nuclear periphery determined by DAPI staining (not shown) is highlighted as a
424 white contour. Also shown are averaged signal of either RNA FISH or RNAPII IF centered on
425 the *MiR290-295* FISH foci or randomly selected positions. Scale bars: 2.5 μ m.

426 **g.** Elevated levels of *MiR290-295* super-enhancer transcript and *Pri-MiR290-295* nascent
427 transcript in TRIM28-degraded iPSCs that ectopically express OSKM factors. The line plots
428 show qRT-PCR data normalized to the 0h of dTAG-13 treatment. * $p < 0.05$, *** $p < 10^{-3}$ two-tailed
429 t test.

430 **h.** Schematic model of the experiment mimicking ERV transcription. mESC lines harboring
431 degradation-sensitive TRIM28-FKBP alleles and 15, 3 or 1 copies of a Piggyback transposon
432 encoding a Dox-inducible GFP transgene were treated with Dox (to induce GFP expression)
433 and/or dTAG-13 (to induce TRIM28 degradation).

434 **i.** Simultaneous transcription of a high copy number of GFP transgenes leads to a reduction of
435 transcription at the *MiR290-295* super-enhancer and its associated gene. The bar plots show
436 qRT-PCR data as fold change normalized to the DMSO control treatment. P values are from
437 two-tailed t tests. ****: $P < 10^{-4}$, ***: $P < 10^{-3}$.

Figure 5



438

439

440 **Figure 5. Early activation of IAP ERVs correlates with onset of lethality and depletion of**
 441 **pluripotent cells in mouse embryos**

442 **a.** Scheme of the zygotic CRISPR/Cas9-perturbation platform.

443 **b.** IF images of mouse E3.5 blastocysts stained for the GAG protein produced by IAPs. Nuclei
 444 are counterstained with DAPI. Note the purple IAP GAG foci highlighted with yellow
 445 arrowheads. Scale bar: 10 μ m.

446 **c.** Quantification IAP GAG foci in multiple embryos of the indicated genotypes.

447 **d.** The timing of IAP de-repression correlates with the onset of lethality. The plots show the day
 448 when the indicated mutations are embryonic lethal versus when IAP foci are first detected in
 449 mutant embryos.

450 **e.** Epiblast cells are depleted in TRIM28 KO embryos. UMAP of E6.5 wild type and E6.5
451 TRIM28 KO embryos mapped on the combined reference cell state map. The proportions of
452 cells that belong to the individual cell states are indicated as a bar on the right of the UMAP
453 plots.

454 **f.** Elevated *IAP* RNA level in TRIM28 KO mouse embryos. The plot shows qRT-PCR data of
455 *IAP* expression in E3.5 wild type and TRIM28 KO embryos. “n” indicates the number of
456 embryos included in the experiment. P value is from a two-tailed t-test.

457 **g.** The inner part of TRIM28 KO blastocysts is populated by GATA6-expressing, NANOG-
458 negative cells. Displayed are representative immunofluorescence images of NANOG and
459 GATA6 in E3.5 wild type, TRIM28 KO and NANOG KO blastocysts. Scale bars: 20µm.

460 **h.** Condensate hijacking model. In pluripotent cells, transcriptional condensates associate with
461 super-enhancers bound by pluripotency transcription factors (e.g. OCT4). In the absence of
462 TRIM28, transcriptional condensates are lost from super-enhancers, and associate with de-
463 repressed ERVs.

464 **Materials and Methods**

465

466

467 Cell culture

468 V6.5 mouse Embryonic Stem Cells (mESCs) and induced Pluripotent Stem Cells (iPSCs) were
469 cultured on irradiated primary Mouse Embryonic Fibroblasts (MEFs) under standard Serum/LIF
470 conditions [knockout DMEM containing 15% fetal bovine serum (FBS), supplemented with 1X
471 penicillin/streptomycin, 1X GlutaMAX supplement, 1X non-essential amino acids, 0.05mM β -
472 mercaptoethanol (all from Gibco) and 1000 U/ml leukemia inhibitory factor (LIF)].

473

474 For ChIP-Seq, TT-SLAM-Seq and RNA-Seq experiments, mESCs were depleted from MEFs by
475 incubating them on gelatin-coated cell culture plates for 45 min at 37°C allowing MEFs to attach
476 while mESCs remain in suspension. MEF depletion was performed two times after which mESCs
477 were seeded on gelatin-coated plates and maintained in Serum/LIF conditions with 2000 U/ml LIF.

478

479 For RNA FISH combined with immunofluorescence, MEF-depleted cells were grown on round
480 18mm glass coverslips (Roth LH23.1). Coverslips were coated with 5 μ g/ml of poly-L-ornithine
481 (Sigma-Aldrich, P4957) for 30 min at 37°C and with 5 μ g/ml of Laminin (Corning, 354232)
482 overnight at 37°C.

483

484 To perturb RNAPII condensates, cells were treated 30 minutes with 1.5% 1,6-hexanediol
485 (Sigma) in Serum/LIF conditions with 2000U/ml LIF ([Extended Data Fig. 7c-e](#)).

486

487 Generation of the TRIM28-FKBP ESC line

488 To knock in the degradation-sensitive FKBP^{F36V} tag at the N-terminus of TRIM28, a repair
489 template containing homology arms spanning upstream and downstream of the target site was
490 cloned into a pUC19 vector (NEB) ([Extended Data Fig. 2a](#)). The repair template included a
491 mRuby2 fluorescent protein sequence, P2A linker and the FKBP tag sequence ([Extended Data Fig.](#)
492 [2a](#))²⁶. mRuby2 sequence was amplified from the mRuby2-N1 plasmid (Addgene #54614) and the
493 P2A-FKBP sequence was amplified from the PITCh dTAG donor vector (Addgene #91792). A
494 guide RNA ([Supplementary Table 1b](#)) targeting the N-terminus of TRIM28 was cloned into the

495 sgRNA-Cas9 vector pX458 (Addgene: 48138). The repair template and the sgRNA-Cas9 vector
496 were transfected into V6.5 mESCs and iPSCs by nucleofection using Amaxa 4D Nucleofector X
497 Unit (Lonza) according to manufacturer's instructions. To screen for positive integrations, the
498 transfected cells were sorted for mRuby2 fluorescent protein expression with flow cytometry. The
499 sorted cells were seeded as single-cells and expanded for few days. Single colonies were picked
500 and genotyped for the correct integration with PCR.

501

502 Generation of the TRIM28-FKBP iPSC line

503 To generate mouse secondary induced pluripotent stem cells (iPSCs), secondary MEFs that harbor
504 Doxycycline (Dox) -inducible *Oct4*, *Sox2*, *Klf4* and *c-Myc* (OSKM) transgenes, and a
505 NANOG::GFP reporter³⁹, were reprogrammed. MEFs were seeded at a low density of about
506 10,000-25,000 cells per well of a 12-well plate that was coated with 0.2% gelatin. Prior to induction
507 of the transgenes, cells were synchronized with a 12-16h incubation in 2.5% FBS containing
508 medium. Afterwards, the medium was switched to 15% FBS/LIF with 2µg/ml Doxycycline. Media
509 was changed every day; colonies emerged after about a week and clonal iPSC lines were resolved
510 within 2 weeks. The iPSC line with the TRIM28 FKBP knock-in alleles was generated as described
511 above.

512

513 Inactivation of NANOG::GFP in the TRIM28-FKBP iPSC line

514 For immunofluorescence combined with RNA FISH experiments (Fig. 4f, Extended Data Fig.
515 14c), GFP at the *Nanog::GFP* locus was inactivated by targeting with a guide RNA
516 (Supplementary Table 1b) against the GFP sequence. CRISPR-Cas9-guide RNA
517 Ribonucleoprotein complex (RNPs) was assembled following manufacturer's guidelines (Alt-R
518 CRISPR; IDT). Briefly, 2µl each of 200µM of crRNA and 200µM of tracrRNA was mixed and
519 denatured at 95°C for 5 minutes, and allowed to anneal to room temperature for 20 minutes. 3µl
520 of crRNA-tracrRNA was mixed with 1µl of 61µM Cas9 20 minutes prior to transfection. TRIM28-
521 FKBP iPSCs were transfected with the assembled RNPs by nucleofection using Amaxa 4D
522 Nucleofector X Unit (Lonza) according to manufacturer's instructions. The cells were then sorted
523 for non-GFP cells using flow cytometry. The sorted cells were expanded and cultured as a clonal
524 line.

525

526 Generation of shRNA knockdown mESC line for IAPEz and IAPEz/MMERVK10c/
527 /MMERVK9c/ MMETn

528 shRNA against the repeat elements was designed using the consensus sequence of the inner part
529 of each element. shRNA sequences are listed in [Supplementary Table 1b](#). shRNA sequences were
530 cloned into an inducible plasmid following the standard cloning protocol recommended for this
531 vector. Lentivirus with the shRNA constructs was generated by transfecting HEK293 cells along
532 with packaging and envelope plasmids. TRIM28-FKBP mESCs were transduced with the virus
533 with 8µg /mL polybrene for 48 hours followed by treatment with 2µg/ml puromycin to select for
534 the transduced cells. Single colonies were picked, characterized and expanded as a clonal line for
535 IAPEz and as a bulk line for the quadruple knockdown line for IAPEz, MMERVK10c,
536 MMERVK9c, MMETn. shRNA expression was induced by treatment with 2µg/ml Doxycycline.
537 For the experiment with pre-induction of shRNAs ([Fig. 3a-c](#), [Extended Data Fig. 11e-g](#)), the cells
538 were treated for 24 hours with Doxycycline followed by DMSO/dTAG-13/Dox+dTAG-13 for
539 another 24 hours. Tet-pLKO-puro was a gift from Dmitri Wiederschain (Addgene plasmid #
540 21915). psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260). pCMV-VSV-G was a
541 gift from Bob Weinberg (Addgene plasmid # 8454).

542

543 Integration of Piggyback transposon encoding a Dox-inducible GFP transgene

544 The PB-tetO-GFP construct (Dox-inducible GFP) was created by digesting an “all-in-one”
545 Piggybac, TREG/Tet-3G plasmid (Addgene plasmid # 97421; a gift from Steven Carr & Samuel)
546 with restriction enzymes NcoI and KpnI and cloning following oligonucleotides to insert a start-
547 codon “ATG” in front of the GFP (PG_ATG_GFP:
548 5’cttcctaccctcgtaaaggctctagagctagccaccatgggtaccgtgagcaagggcgaggagctgttcaccgggtggtg 3’) via
549 NEBuilder HiFi Assembly. The construct was randomly integrated in the mESC V6.5 Trim28-
550 FKBP subclone by co-transfecting 4×10^5 cells with 8.5µg PB-tetO-GFP and 1.5µg Super
551 PiggyBac transposase expression vector (SBI, PB210PA-1) using FuGENE HD Transfection
552 Reagent (Promega). After 4 days of Puromycin selection (2µg/ml) single colonies were picked,
553 expanded and tested for doxycycline-inducibility of the GFP construct monitored by GFP
554 detection with FACS. Three clones expressing low, intermediate and high levels of GFP were
555 selected and expanded for subsequent experiments.

556

557 Deletion of ERVs in the TRIM28-FKBP mESC line

558 To generate mESC line with three ERV deletions at the *Cthrc1* locus, deletions of MMETn,
559 MMERVK and IAP sequences were performed sequentially with CRISPR/Cas9. Guide RNAs
560 (Supplementary Table 1b) flanking the individual ERV elements were cloned into the sgRNA-
561 Cas9 vector pX458 and the two vectors for each cut were delivered to cells with Lipofectamine
562 2000 (Thermo Fisher, 11668027) according to manufacturer's instructions. Transfected cells were
563 sorted based on GFP expression two days later with flow cytometry. Single colonies were picked,
564 genotyped (Extended Data Fig. 7f, Supplementary Table 1b) and clones with homozygous deletion
565 were selected for the next ERV deletion. Deletions were also confirmed by sequencing the PCR
566 products.

567

568 TRIM28 degradation

569 Prior to treatment, cells were seeded onto 0.2% gelatin coated plates after two rounds of MEF
570 depletion. For degradation of TRIM28, 500nM of dTAG-13 compound²⁶ was mixed with mESC
571 media (Supplemented with 2000 U/mL LIF) and incubated for the indicated time duration.

572

573 Western blot

574 Cultured cells were lysed in RIPA buffer for 30 minutes at 4°C, and centrifuged for 20 minutes at
575 maximum speed. The supernatant was then transferred to a new tube and quantified by BCA assay
576 (Thermo Scientific). 10µg of extracted protein was run on a 4-12% NuPAGE SDS gel and
577 transferred onto a PVDF membrane using iBlot2 Dry Gel Transfer Device (Invitrogen) according
578 to manufacturer's instructions. The blots were blocked with 5% skim milk in TBST and incubated
579 with primary antibodies. Primary antibodies used in this study include TRIM28 (ab22553; 1:500),
580 ACTB (ab8226; 1:1000), OCT4 (ab19857; 1:500), OCT4 (sc-5279; 1:500), HSP90 (BD610419;
581 1:4000), SOX2 (ab79351; 1:500). HRP-conjugated secondary antibodies were used against the
582 host species at 1:3000 – 1:5000 dilution and visualized with HRP substrate SuperSignal West Dura
583 (Thermo Scientific) (Fig. 1d, 4b, Extended Data Fig. 2b, 14a).

584

585 Proteomics Sample Preparation and LC-MS/MS Instrument Settings for Shotgun Proteome
586 Profiling and Data Analysis

587 Proteomics sample preparation was done according to a published protocol with minor
588 modifications ⁵². In brief, three biological replicates of dTAG-13 -treated samples with 4 million
589 cells per replicate were lysed under denaturing conditions and sequentially digested with LysC and
590 Trypsin (Roche, Basel, Switzerland). Peptide desalting was performed according to the
591 manufacturer's instructions (Pierce C18 Tips, Thermo Scientific, Waltham, MA). Desalted
592 peptides were further separated into four fractions by strong cation exchange chromatography
593 (SCX, 3M Purification, Meriden, CT). LC-MS/MS was carried out by nanoflow reverse phase
594 liquid chromatography (Dionex Ultimate 3000, Thermo Scientific) coupled online to a Q-Exactive
595 HF Orbitrap mass spectrometer (Thermo Scientific), as reported previously ⁵³. Briefly, the LC
596 separation was performed using a PicoFrit analytical column (75 µm ID × 50 cm long, 15 µm Tip
597 ID; New Objectives, Woburn, MA) in-house packed with 3-µm C18 resin (Reprosil-AQ Pur, Dr.
598 Maisch, Ammerbuch, Germany). Raw MS data were processed with MaxQuant software
599 (v1.6.10.43) and searched against the mouse proteome database UniProtKB with 55,471 entries,
600 released in May 2020. The MaxQuant processed output files can be found in ([Supplemental Table](#)
601 [3](#)), showing peptide and protein identification, accession numbers, % sequence coverage of the
602 protein, q-values, and label-free quantification (LFQ) intensities. The mass spectrometry data have
603 been deposited to the ProteomeXchange Consortium
604 (<http://proteomecentral.proteomexchange.org>) via the PRIDE ⁵⁴ partner repository with the dataset
605 identifier PDX021895. The correlation analysis of biological replicates and the calculation of
606 significantly different proteins were done with Perseus (v1.6.14.0). Only groups with valid values
607 in at least one group were used, missing values were replaced by values from the normal
608 distribution. Statistical analysis was done by a two-sample t-test with Benjamini-Hochberg (BH,
609 FDR of 0.05) correction for multiple testing ([Extended Data Fig. 2c, 14d](#)).

610

611 RNA isolation and quantitative Real-Time PCR (qRT-PCR)

612 RNA from cultured cells was isolated using RNeasy kit (Qiagen) according to manufacturer's
613 instructions. 1µg of RNA was used for cDNA synthesis using RevertAid First Strand cDNA
614 synthesis kit (Thermo Scientific) with random hexamer primers according to manufacturer's
615 instructions. RNA from single blastocysts (E3.5) was isolated using PicoPure RNA isolation kit
616 (Thermo Fischer Scientific) and cDNA was synthesized with High Capacity cDNA Reverse
617 Transcription kit (Applied Biosystems). qRT-PCR was performed with primers ([Supplementary](#)

618 [Table 1b](#)) and 2X PowerUP SYBR green master mix (Applied Biosystems). Note that in [Fig. 3a-](#)
619 [b](#), and [Extended Data Fig 11a-f](#), the qPCR primers used for MMETn and MERVK9c elements fail
620 to detect induction after dTAG-13 treatment, which is explained by these elements having
621 degenerate genomic sequences.

622

623 Immunofluorescence (IF) in mouse embryos and blastocysts

624 E3.5 blastocysts and E6.5 embryos were dissected from the uterus in 1X HBBS and fixed in 4%
625 Paraformaldehyde (PFA) at 4°C overnight. The embryos were washed three times in 1X PBS with
626 0.1% TritonX-100 and then permeabilized in 1X SuperBlock PBS with 0.5% TritonX-100 for one
627 hour at room temperature. Blocking against unspecific binding was done by incubating embryos
628 in blocking buffer (1X SuperBlock PBS with 0.2% TritonX-100, 10% Donkey Serum, 3% Bovine
629 Serum Albumin) for two hours at room temperature. Primary antibodies were diluted in antibody
630 buffer (1X SuperBlock PBS with 0.2% TritonX-100, 10% Donkey Serum, 0.3% Bovine Serum
631 Albumin) and incubated at 4 °C overnight. Primary antibodies used include TRIM28 (ab22553;
632 1:200), OCT4 (ab19857; 1:200), NANOG (REC-RCAB002P-F; 1:400), KLF4 (AF3158; 1:200),
633 SOX2 (ab79351; 1:200), GATA6 (AF1700; 1:200), GATA4 (sc-25310; 1:200), SOX17 (AF1924;
634 1:200), IAP-GAG (MBS8566075; 1:100). Embryos were washed in blocking buffer three times
635 for 30 minutes each and incubated with host-specific secondary antibodies conjugated to
636 fluorescent dyes for three hours in the dark at room temperature. After washing with blocking
637 buffer, nuclei were counterstained with 0.5µg/mL DAPI for 30 minutes in the dark at room
638 temperature. Embryos were mounted in drops of 1X PBS and covered with mineral oil prior to
639 imaging. Images were acquired with LSM880 (Zeiss) microscope with a 40X objective. Images
640 were processed with ZEN 3.1 (Zeiss) and ImageJ ([Fig. 5b](#), [5g](#) [Extended Data Fig. 18a-b](#)).

641

642 SSEA-1 staining

643 Cultured cells were dissociated into single-cells with Accutase enzyme mix, washed in 1X PBS
644 and fixed with 4% PFA for 15 minutes at room temperature. Following three washes with 1X PBS,
645 the cells were incubated with fluorescent conjugated SSEA-1 antibody (BioLegend 125608,
646 125609; 1:1000) for one hour in the dark at 37°C. After three washes in 1X PBS, nuclei were
647 counterstained with 0.24 µg/ml DAPI and imaged with LSM880 confocal microscope at 63X oil

648 objective ([Extended Data Fig. 2d-e](#)). For FACS analysis, the cells were washed two times in 1X
649 PBS+10%FBS and analyzed with BD FACS Celesta ([Extended Data Fig. 19a](#)).

650

651 RNA-FISH

652 TRIM28-FKBP iPSCs were seeded onto 0.2% gelatin-coated plates prior to treatment. For the
653 treatment, 500nM of dTAG-13 and/or 2 μ g/ml Doxycycline was mixed with the media and
654 incubated for the indicated durations. RNA-FISH was performed on glass coverslips coated with
655 Poly-L-Lysine (Sigma-Aldrich) prior to seeding. Cells were dissociated with Accutase enzyme
656 mix (Sigma-Aldrich), washed in 1X PBS, resuspended in minimal volume of ESC media. 10-20 μ L
657 drops of cells were added to the coverslips and were allowed to attach for 10 minutes at room
658 temperature. 4% PFA fixation for 15 minutes was followed by two 1X PBS washes and
659 permeabilized in 70% ethanol at 4°C overnight. RNA-FISH was performed with reagents from the
660 Stellaris RNA-FISH method (LGC Technologies) following manufacturer's instructions.
661 Hybridization was performed with an oligo probe that was labeled with Cy5 dye at the 5'end
662 (TTCTTGATGTCCTAACCCCTTTTCCTTC). After the final wash, the coverslips were mounted
663 onto glass slides with ProLong Gold Anti-fade (Invitrogen) mounting media. Images were
664 acquired with Z1 Observer (Zeiss) microscope at 100X magnification. Images were processed with
665 ZEN 3.1 (Zeiss) and ImageJ software ([Fig. 4c-d](#)).

666

667 RNA-FISH combined with Immunofluorescence (IF)

668 RNA-FISH combined with Immunofluorescence was performed essentially as described ³¹. For
669 immunofluorescence, dTAG-13 or DMSO treated cells were fixed in 4% PFA for 10 minutes at
670 RT and stored in PBS at 4°C. All buffers and antibodies were diluted in RNase-free PBS (Thermo
671 Fisher, AM9624). Cells were permeabilized with 0.5% Triton X-100 (Thermo Fisher, 85111) for
672 10 min at RT, followed by three consecutive 5 min PBS washes. Cells were then incubated in the
673 primary antibody (RNAPII (abcam, ab817) at 1:500, NFY-A (Santa Cruz, sc-17753 X) at 1:250,
674 NRF1 (abcam, ab55744) at 1:500, MED1 (abcam, ab64965) at 1:500 and MED23 (Bethyl Labs,
675 A300-425A) in PBS overnight. After two 5 min PBS washes, cells were incubated in the secondary
676 antibody (Invitrogen, goat anti-mouse Alexa 488 (A-11001) or goat anti-rabbit Alexa 488 (A-
677 11008)) at 1:500 in PBS for 60 min at RT. Cells were washed twice in PBS for 5 min and re-fixed
678 with 4% PFA in PBS for 10 min at RT. Following two 5 min PBS washes, cells were washed once

679 with 20% Stellaris RNA FISH Wash Buffer A (Biosearch Technologies, Inc., SMF-WA1-60),
680 10% Deionized Formamide (EMD Millipore, S4117) in RNase-free water (Invitrogen, 10977035)
681 for 5 min at RT. Cells were hybridized with 90% Stellaris RNA FISH Hybridization Buffer
682 (Biosearch Technologies, SMF-HB1-10), 10% Deionized Formamide and 12.5 or 25 μ M Stellaris
683 RNA FISH probes. Probes were hybridized in a humidified chamber O/N at 37°C. Cells were
684 washed with Wash Buffer A for 30 min at 37°C and stained with 0.24 μ g/mL DAPI in Wash Buffer
685 A for 3 min at RT. Cell were washed with Stellaris RNA FISH Wash Buffer B (Biosearch
686 Technologies, SMF-WB1-20) for 5 min at RT, mounted onto glass microscopy slides with
687 Vectashield mounting medium (Vector Laboratories, H-1900) and sealed using transparent nail
688 polish. Images were acquired with LSM880 Airyscan microscope equipped with a Plan-
689 Apochromat-63x/1.40 oil DIC objective or Z1 Observer (Zeiss) microscope with 100X
690 magnification. Images were processed with ZEN 3.1 (Zeiss) and ImageJ software (Fig. 1i, 2a-c,
691 2f-g, 3c, 4f, Extended Data Fig. 6a, 7a-b, 7d, 8b, 11g). RNA FISH probes were designed and
692 generated by Biosearch Technologies Stellaris RNA FISH to target introns of *MiR290-295* primary
693 transcript and *Cthrc1*, and *IAPez* transcripts. Sequences of RNA-FISH probes are available in the
694 [Supplementary Table 1a](#).

695

696 TrueSeq Stranded mRNA-seq

697 mESCs were cultured with either DMSO or 500 nM dTAG-13 for 2, 6, 24 and 96 hours. RNA was
698 isolated using RNeasy kit (Qiagen) and 1 μ g of RNA was used for preparing the libraries. TrueSeq
699 Stranded mRNA capture kit was used to prepare the libraries (KAPA biosystems) according to
700 manufacturer's instructions. Unique Dual-Indexed (UDI; KAPA biosystems) adapters were ligated
701 and the library was amplified for 8 cycles. The libraries were then sequenced as Paired-end 100
702 (PE100) on a Novaseq6000 with 50 million fragments per library.

703

704 TT-SLAM-Seq

705 TT-SLAM-Seq was performed as described previously²⁷. Briefly, cells were treated with DMSO
706 or 500 nM dTAG-13 for 2, 6 or 24 hours and subjected to 15 minutes of 4-Thiouridine (4sU)
707 labeling using 500 μ M 4sU. Total RNA was extracted with Trizol (Ambion) and 24:1
708 chloroform:isoamylalcohol (Sigma), while using 0.1 mM DTT in isopropanol precipitation and
709 ethanol washes. For each sample, 50 μ g of total RNA was fragmented with Magnesium RNA

710 Fragmentation Module (NEB), and fragmentation buffer was removed from samples with ethanol
711 precipitation in presence of 0.1 mM DTT. RNA was then resuspended in 350 μ l RNase free water,
712 diluted in biotinylation buffer (200 mM HEPES pH 7.5, and 10 mM EDTA) and topped up with 5
713 μ g MTS-Biotin (previously diluted to 50 μ g/ml in dimethylformamide) to reach a final volume of
714 500 μ l. Biotinylation reaction was incubated for 30 minutes at room temperature while keeping
715 samples in rotation and protected from light. Unbound biotin was removed with Acid-
716 Phenol:Chloroform extraction (124:24:1, Ambion) and isopropanol precipitation. Biotinylated
717 RNA was resuspended in 100 μ l RNase-free water, denatured in 65 °C for 10 minutes and then
718 cooled on ice for 5 minutes. The biotinylated RNA was captured with 100 μ l μ MACS streptavidin
719 beads (Miltenyi) by incubating for 15 minutes in rotation while keeping samples protected from
720 light. μ MACS columns were equilibrated on magnetic stand with nucleic acid equilibration buffer
721 and two times with biotinylation buffer (20 mM HEPES, 1 mM EDTA, pH 8). Beads were
722 transferred to columns, washed three times with wash buffer (100 mM Tris-HCl pH7.5, 10 mM
723 EDTA, 1 M NaCl and 0.1 % Tween 20) and labeled RNA was eluted two times with total 200 μ l
724 of 100 mM DTT. RNA was cleaned up with RNEasy Minelute columns (Qiagen) and eluted to
725 RNase-free water with 1 mM DTT. 4sU residues of RNA were alkylated with iodoacetamide
726 treatment (10 mM iodoacetamide in 50 mM NaPO₄, pH 8, and 50 % DMSO) by incubating samples
727 in 50 °C for 15 minutes, followed by quenching with 20 mM DTT. RNA samples were purified
728 with ethanol precipitation and treated with Turbo DNase (Invitrogen). Sequencing libraries were
729 prepared with NEBNext Ultra II Directional RNA Library Prep Kit and NEBNext Multiplex
730 Oligos (NEB), according to manufacturer's instructions, except using 8 minutes incubation time in
731 fragmentation step.

732

733 H3K27Ac and H3K9me3 Chromatin immunoprecipitation -sequencing (ChIP-Seq)

734 For ChIP-Seq experiments, DMSO and dTAG-13 treated cells were detached with TrypLE
735 Express (Gibco), washed once with PBS, fixed in rotation with 1 % formaldehyde for 10 minutes
736 in room temperature followed by 5 minutes of quenching with 125 mM glycine. For H3K27Ac
737 and H3K9me3 ChIPs, three million mESCs were used per replicate sample, and 750,000 S2 cells
738 were added for exogenous genome spike-in normalization⁵⁵. Cells were lysed in LB1 (50 mM
739 HEPES-KOH, 140 nM NaCl, 1 mM EDTA, 10 % glycerol, 0.5 % Igepal CA-630 and 0.25 %
740 Triton X-100, 5 mM Na-butyrate and 1x protease inhibitor cocktail) and collected by

741 centrifugation. Lysis was continued in LB2 (10 mM Tris-HCl pH 8.0, 200 mM NaCl, 1 mM
742 EDTA, 0.5 mM EGTA, 5 mM Na-butyrate and 1x protease inhibitor cocktail) followed by
743 centrifugation. Nuclei were lysed in LB3 (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA,
744 0.5 mM EGTA, 0.1 % Na-deoxycholate, 0.5 % N-Lauroylsarcosine, 5 mM Na-butyrate and 1x
745 protease inhibitor cocktail) and chromatin was fragmented with Bioruptor NextGen for 35 cycles
746 (high setting). Lysates were clarified and 10 % of the sample was set aside as input. The remaining
747 sample was split in two to capture protein-DNA complexes with 1 μ g H3K27Ac (ab4729; Abcam)
748 and 1 μ g H3K9me3 (ab8898; Abcam) antibodies by incubating them in rotation overnight in 4 °C.
749 This was followed by 24 hours of incubation with Protein A Dynabeads (Invitrogen) that had been
750 washed three times with 0.25 % BSA in PBS. Beads from immunoprecipitation were washed 7
751 times with RIPA buffer (50 mM HEPES-KOH pH7.5, 1 mM EDTA, 1 % Igepal CA-630, 0.7 %
752 Na-deoxycholate, 500 mM LiCl, 5 mM Na-butyrate and 1 x protease inhibitor cocktail), once with
753 TE buffer (10 mM Tris-HCl pH8.0, 1 mM EDTA and 50 mM NaCl) and eluted from beads with
754 Elution buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA and 1% SDS). Samples were decrosslinked
755 for 16 hours at 65 °C in presence of 550 mM NaCl and proteinase K (Ambion), treated with RNase
756 A (Thermo Scientific) and DNA was extracted with Phenol:Chloroform:Isoamylalcohol followed
757 by chloroform extraction and ethanol precipitation. Sequencing libraries were prepared from 10
758 ng of DNA with KAPA HyperPrep Kit (Roche) and paired-end sequenced with NovaSeq 6000
759 (Illumina) to produce ~100 million fragments for each library.

760

761 RNAPII and MED23 ChIP-Seq

762 Cells were treated with DMSO or 500 nM dTAG-13 for 24 hours. RNAPII and MED23 ChIP-Seq
763 samples were prepared as described above, except for MED23 samples, protein-protein
764 crosslinking was performed by incubating cells in rotation with 2 mM disuccimidyl glutarate
765 (Thermo Scientific; Pierce) in PBS, followed by two washes with PBS and formaldehyde fixation
766 as above. 30 million and 10 million cells were used for RNAPII and MED23 IPs, respectively.
767 RNAPII samples included an exogenous genome spike-in of 7.5 million S2 cells. Cell lysis was
768 performed as above and samples were sonicated in sonication buffer (50 mM HEPES-KOH pH
769 7.5, 140 mM EDTA, 1 mM EDTA, 1 mM EGTA, 1 % Triton X-100, 0.1 % Na-deoxycholate, 0.1
770 % SDS and 1x protease inhibitors (Roche)) for 35 cycles in case of RNAPII samples and 50 cycles
771 for MED23 samples by using Bioruptor NextGen (high setting). When preparing beads for IPs, 50

772 μ l of Protein A Dynabeads (Invitrogen) was washed three times in blocking buffer (0.5 % BSA in
773 PBS) and then bound to 5 μ g of RNAPII antibody (8WG16; Biolegend) and 2 μ g of Spike-in
774 antibody (61686, Active Motif) or 5 μ g of MED23 antibody (A300-425A; Bethyl Laboratories)
775 during an overnight incubation in blocking buffer. Antibody-conjugated beads were washed three
776 times with blocking buffer, resuspended to 100 μ l of blocking buffer prior to adding them to
777 sheared chromatin in a total volume of 2.5 ml sonication buffer for RNAPII and 1 ml for Med23.
778 Immunoprecipitation was performed in rotation overnight in 4 °C. Beads were washed twice with
779 sonication buffer, once with sonication buffer containing 500 nM NaCl, once with LiCl wash
780 buffer (20 mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5 % Igepal CA-630, 0.5 % Na-
781 deoxycholate, 1x protease inhibitors) and once with TE buffer (10 mM Tris pH 8.0, 1 mM EDTA,
782 1x protease inhibitors). Samples were eluted from beads with 200 μ l elution buffer as above and
783 crosslinks were reversed by incubating samples in 65 °C for 16 hours. Samples were topped up
784 with 200 μ l TE buffer and 8 μ l of RNase A, incubated in 37 °C for 2 hours followed by addition
785 of 7 μ l of 300 mM CaCl₂, 2 μ l Proteinase K (Ambion) and 30 minutes incubation in 37 °C. DNA
786 purified from samples with phenol:chloroform:isoamyl alcohol extraction followed by ethanol
787 precipitation. Libraries were prepared and sequenced as above for total ~50 million fragments for
788 each library.

789

790 In-situ Hi-C

791 In-situ Hi-C experiments were performed for two biological replicates of TRIM28-FKBP mESCs
792 after 24h DMSO or dTAG-13 treatments as described previously⁵⁶, with minor modifications.
793 Briefly, 3 million cells per sample were fixed in suspension with 1 % formaldehyde for 10 minutes
794 and quenched with 0.125 M glycine for 5 minutes in rotation. Cells were washed with PBS and
795 lysed in Hi-C lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% Igepal CA-
796 630, 1.15 % Triton X-100 and 1x protease inhibitors (Roche)) for 10 minutes on ice. Nuclei were
797 washed with cold PBS, NEBuffer 2 (NEB) and resuspended in 50 μ l of 0.5 % SDS, incubated in
798 62 °C for 7 minutes and SDS was quenched with 145 μ l water and 25 μ l 10 % Triton X-100
799 followed by 15 min incubation in 37 °C. For restriction enzyme digestion, 25 μ l of 10X NEBuffer2
800 and 250 U of MboI (NEB) were added and samples were incubated overnight in 37 °C, followed
801 by additional 1 hour incubation after adding another 250 U of MboI. Enzymes were inactivated
802 for 20 minutes in 65 °C. Samples were spun in 5000 g, 200 μ l of supernatant was removed and

803 sample was resuspended in 200 μ l of 1.2X NEBuffer 2. To fill-in DNA overhangs, 50 μ l of fill-in
804 buffer (37.5 μ l of 0.4 mM biotin-14-dATP (Thermo Fisher, 19524016), 1.5 μ l of dCTP, 1.5 μ l of
805 dGTP, 1.5 μ l of dTTP, 10 mM each, and 8 μ l of 5U/ μ l DNA PolI Large (Klenow) Fragment (NEB,
806 M0210L)) was added and the samples were incubated in 37 °C for 90 minutes. For ligation
807 reaction, samples were topped up with 663 μ l of water, 120 μ l of NEB T4 DNA ligase buffer
808 (NEB), 100 μ l of 10 % Triton X-100 and 12 μ l of 10 mg/ml BSA (NEB, B9000S) and 2000 U of
809 T4 DNA ligase (NEB, M0202) and incubated overnight in 18 °C in rotation. Crosslinks were
810 reversed with Proteinase K and 0.88 % SDS in 10 mM Tris-HCl (pH 7.5) during 30 min in 55 °C,
811 followed by incubation in 68 °C in presence of 2.3 M NaCl for 2 hours. For library preparation,
812 DNA was extracted from samples with ethanol and sodium acetate precipitation, sheared with
813 Covaris E220 and pulled down with 150 μ l of T1 Streptavidin Dynabeads (Thermo Fisher). The
814 end-repair for captured DNA was performed in room temperature for 30 minutes using 100 μ l
815 reaction with 0.5 U of T4 Polynucleotide Kinase (NEB), 12 U of T4 DNA polymerase (NEB) 5 U
816 of DNA pol I Large (Klenow) Fragment in NEB T4 DNA ligase buffer with 10 mM ATP and 0.5
817 mM dNTP. After washing the bead-bound DNA, samples were resuspended to NEBuffer 2 with
818 0.5 mM dATP and 25 U of Klenow exo minus (NEB, M0212) and incubated in 37 °C for 30
819 minutes. After washing the beads, universal sequencing adapters from NEBnext Ultra DNA
820 Library Kit (NEB) were ligated in NEB Quick ligation reaction buffer according to manufacturer's
821 guidelines. Libraries were amplified for 6 PCR cycles and purified using Ampure XP beads
822 (Beckman Coulter). Libraries were paired-end sequenced with NovaSeq 6000 for 400 million
823 fragments for each library.

824

825 Generation of DNA constructs for protein purification

826 For the purification of fluorescently labeled fusion proteins we amplified the C-terminal domain
827 of POLR2A (Fwd: 5'-TACTCACCGACATCACCAGCCTATG-3', Rev: 5'-
828 GTTCTCCTCATCGCTGTCA-3'), full length CBX5 (HP1 α) (Fwd: 5'-
829 ATATGGGAAAGAAGACCAAGAGGACAG-3', Rev: 5'-GCTCTTCGCGCTTTCTTT -3'), the
830 intrinsically disordered region of MED1 (Fwd: 5'-ATTGCAGAGACAGTTGAAGACATGG-3',
831 Rev: 5'-ATTGCCAATCAGGGCCACA-3') and the intrinsically disordered region of NFYC
832 (Fwd: 5'-CCTGTCCAGTACTACTTCACG-3', Rev: 5'-GTCTCCAGTCACCTGGGG-3') from
833 cDNA generated from v6.5 mouse embryonic stem cells. The amplified fragments were cloned

834 into pET45-mCherry (Addgene Cat# 145279) or pET45-mEGFP (this paper) backbones by Gibson
835 assembly using NEBuilder® HiFi DNA Assembly Master Mix (NEB). All sequences of interest
836 were cloned C-terminally to the respective fluorescence marker.

837

838 Protein purification

839 Protein overexpression in BL21 (DE3) (NEB M0491S) was performed as described⁵⁷. Pellets were
840 resuspended in 25 mL of ice-cold Buffer A (50 mM Tris pH 7.5, 500 mM NaCl, 20 mM Imidazole)
841 supplemented with cOmplete protease inhibitors (Sigma, 11697498001) and sonicated for 10
842 cycles (15 s ON, 45 s OFF) on a Qsonica Q700 sonicator. The resulting lysate was cleared by
843 centrifugation at 15,500 g for 30 minutes at 4°C. For protein purification we used the Äkta avant
844 25 chromatography system. The supernatant was loaded onto a cOmplete His-Tag purification
845 column (Merck, 6781543001) pre-equilibrated in Buffer A. The loaded column was washed with
846 15 column volumes (CV) of Buffer A. Bound fusion protein was eluted in 10 CV of Elution Buffer
847 (50 mM Tris pH 7.5, 500 mM NaCl, 250 mM Imidazole) and immediately diluted 1:1 in Storage
848 Buffer (50 mM Tris pH 7.5, 125 mM NaCl, 1 mM DTT, 10% Glycerol). The resulting eluate was
849 concentrated by centrifugation at 10,000 g for 30 minutes at 4°C using 3000 MWCO Amicon Ultra
850 centrifugal filters (Merck, UFC803024). The concentrated fraction was diluted 1:100 in Storage
851 Buffer, re-concentrated and stored at -80°C.

852

853 In vitro transcription of IAP RNA

854 To generate *in vitro* transcribed RNA for the *gag* region of IAPez, template PCR amplicon was
855 generated from cDNA using primers listed in [Supplementary Table 1b](#). The regions of interest
856 cloned for *in vitro* transcription of the Mir290-295 super-enhancer RNA and Major Satellite
857 Repeat RNA were previously described^{35,38}, and the primers used are listed in [Supplementary](#)
858 [Table 1b](#). 1µg of DNA was used for *in vitro* transcription using Fluorescein 12-UTP or Cy5-UTP
859 RNA labeling kit (Jena Biosciences) and incubated at 37°C for 4 hours followed by 15mins
860 incubation with TURBO DNaseI. Labeled RNA was purified using Clean and Concentrator Kit-5
861 (Zymo research) and eluted in Tris-HCl pH8.0. For *Mir290-295* super-enhancer RNA, transcribed
862 RNA of positive and negative strand was mixed 1:1 at equimolar concentrations.

863

864 In vitro droplet assay

865 For the *in vitro* droplet formation assay (Fig. 3d-i, Extended Data Fig. 12, Extended Data Fig. 13),
866 the purified mCherry- or mEGFP-fusion proteins were measured for concentration and
867 subsequently diluted to the desired concentration in Storage Buffer (50 mM Tris pH 7.5, 125 mM
868 NaCl, 1 mM DTT, 10% Glycerol). Protein solutions were mixed with Fluorescein- or Cy5-labeled
869 RNA and then diluted 1:1 with 20% PEG-8000 in de-ionized water (w/v). After 30 minutes of
870 incubation at room temperature, 10 μ l of this mix was pipetted onto a chambered coverslip (Ibidi,
871 80826-90). Images were acquired using an LSM880 confocal microscope equipped with a Plan-
872 Apochromat-63x/1.40 oil DIC objective with a 2.5x post-magnification if indicated. Data for the
873 quantification of condensate formation in *in vitro* mixing assays was acquired from at least 5
874 images of two independent image series per condition. For the detection of droplet regions, we
875 used the ZEN blue 3.1 Image Analysis and Intellesis software packages. Image segmentation was
876 achieved by use of a previously trained ZEN Intellesis algorithm for classification of each
877 individual pixel into foreground (droplet area) or background (image background). Generated
878 probability maps with a minimal confidence of at least 90%, a minimum area of 3 pixels and
879 watershed for primary objects were implemented into the ZEN Image Analysis module to classify
880 regions of interest. For the calculation of the partition ratio, the mean intensity values of droplets
881 and background for the respective channel was used. Enrichment of RNA in droplets was
882 calculated by background subtraction from the mean intensity values of droplet areas in the
883 respective RNA channel (Fig. 3f, 3i, Extended Data Fig. 12e) or as partition ratio as described
884 above. All figures were generated using R-Studio.

885

886 Fluorescence recovery after photobleaching (FRAP)

887 MED1 IDR droplets for photobleaching experiments were formed as described above at a
888 concentration of 10 μ M (Extended Data Fig. 12f). Instead of a preassembly incubation for 30
889 minutes at room temperature, the droplets were immediately imaged after they were pipetted on
890 the slide. Droplets were bleached with 488 nm light, and fluorescence recovery was imaged every
891 second over a total of 60 seconds. Bleaching was performed on a central region of a settled single
892 droplet using 10 iterations of 100% laser power. The resulting recovery curves were fitted to a
893 power law model. All figures were generated using GraphPad PRISM9.

894

895 Generating wild type and mutant mouse embryos

896 Zygotes were generated by *in vitro* fertilization (IVF) as previously described⁵⁸. Briefly, B6D2F1
897 female mice of 6-8 weeks of age were superovulated with two rounds of hormone injections (5IU
898 of PMSG followed by 5IU of HCG after 46 hours). Oocytes were isolated and cultured in pre-
899 gassed KSOM prior to IVF. F1 (C57BL/6J x Castaneous) sperm isolated from the cauda
900 epididymis was thawed and used for IVF. 6 hours after fertilization, zygotes were washed in M2
901 media for multiple rounds and then prepared for electroporation. Alt-R CRISPR-Cas9 and guide
902 RNAs Ribonucleoproteins (RNP) were prepared as previously described⁴². Guide RNAs used to
903 target the genes are listed in [Supplementary Table 1b](#). Zygotes were washed in 3 drops of
904 OptiMEM Reduced Serum Media (Thermo Fisher Scientific) prior to electroporation. NEPA21
905 electroporator (NEPAgene) was used for electroporating zygotes with the following settings for a
906 small chamber: Four poring pulses of 34 V for 2.5ms with an interval of 50ms was used to generate
907 pores in the Zona pellucida layer. Voltage decay was set at 10% and (+) polarity. To enable intake
908 of the RNPs, Five Transfer pulses of 5V was applied for 50ms with an interval of 50ms. Voltage
909 decay for the transfer was set at 40% with an alternating polarity of (+) and (-). Electroporated
910 zygotes were washed in 3 drops of KSOM medium and cultured in pre-gassed KSOM drops until
911 blastocyst stage under standard embryo culture conditions. Blastocysts were scored for viability
912 and morphology, and re-transferred bilaterally in a clutch of 15 blastocysts per uterine horn into
913 day 2.5 pseudopregnant CD-1 surrogate female mice. E6.5 embryos were dissected from the uterus
914 in 1X HBSS and used for further analysis. E5.5 wild type embryos were generated with the setup
915 and mock electroporation with guide targeting GFP sequence was used.

916

917 All procedures have been performed in our specialized facility, following all relevant animal
918 welfare guidelines and regulations, approved by the Max Planck Institute for Molecular Genetics
919 and the local authorities LAGeSo, Berlin (license number: G0247/18-SGr1).

920

921 Single-cell RNA sequencing of embryos

922 E5.5 wild type and E6.5 TRIM28 mutant embryos were dissected from the decidua in 1X HBSS
923 and then washed in 1X PBS. Reichert's membrane was carefully removed with sharp forceps and
924 glass capillaries and the embryos were washed in 1X PBS with 0.4% BSA. The embryos were
925 disaggregated with TrypLE Express (Gibco) with gentle pipetting every 10 minutes up to a total
926 of 40 minutes at 37°C. The dissociated cells were counted for viability and then washed in 1X PBS

927 with 0.4% BSA for a total of three washes at 4°C and 1,200rpm for 5 minutes. The cells were
928 subjected to single-cell RNA sequencing using 10X Genomics Chromium Single Cell 3' v2 kit.
929 Single-cell libraries were generated following manufacturer's instructions with an exception to the
930 cycle number used. Libraries were sequenced on a Novaseq6000 with asymmetric reads and a
931 depth of 300-350 million fragments per library.

932

933 Average image and radial distribution analysis

934 Image analysis pipeline used for the colocalization analysis of RNA FISH combined with IF was
935 described previously³¹. Briefly, MATLAB scripts were used to identify RNA FISH foci in z stacks
936 through intensity thresholding (same threshold was used for image sets shown on the same figure
937 panels) and create RNA FISH signal centroids (x, y, z) that were stitched together and positioned
938 in a box of size $l = 1.5 \mu m$. For identified FISH foci, signal from corresponding location in the IF
939 channel was collected in the $l \times l$ square centered at the RNA FISH focus at every corresponding
940 z-slice. The IF signal centered at FISH foci for each FISH and IF pair were then combined to
941 calculate an average intensity projection, providing averaged data for IF signal intensity within a l
942 $\times l$ square centered at FISH foci. The same process was carried out for the FISH signal intensity
943 centered on its own coordinates, providing averaged data for FISH signal intensity within a $l \times l$
944 square centered at FISH foci. As a control, this same process was carried out for IF signal centered
945 at random positions. These average intensity projections were then used to generate 2D contour
946 maps of the signal intensity or radial distribution plots. Contour plots are generated using in-built
947 functions in MATLAB. The intensity radial function ((r)) is computed from the average data. For
948 the contour plots of the IF channel, an intensity colormap consisting of 14 bins with gradients of
949 black, violet and green was generated. For the FISH channel, black to magenta was used. The
950 generated colormap was employed to 14 evenly spaced intensity bins for all IF plots. The averaged
951 IF centered at FISH or at randomly selected nuclear locations were plotted using the same color
952 scale. For the radial distribution plots, the Spearman correlation coefficients r were computed and
953 reported between the FISH and IF (centered at FISH) signal. A two-tailed student's t-test,
954 comparing the Spearman correlation calculated for all pairs, was used to generate p values (Fig.
955 [1i, 2f-g, 3c, 4f, Extended Data Fig. 6a](#)).

956

957 Bioinformatics

958 All analyses were carried out using R 3.6.3 if not stated otherwise.

959

960 RNA-Seq processing

961 Raw reads were subjected to adapter and quality trimming with cutadapt ⁵⁹ (version 2.4;
962 parameters: --nextseq-trim 20 --overlap 5 --minimum-length 25 --adapter AGATCGGAAGAGC -
963 A AGATCGGAAGAGC), followed by poly-A trimming with cutadapt (parameters: --overlap 20
964 --minimum-length 25 --adapter "A[100]" --adapter "T[100]"). Reads were aligned to the mouse
965 reference (mm10) using STAR ⁶⁰ (version 2.7.5a; parameters: --runMode alignReads --
966 chimSegmentMin 20 --outSAMstrandField intronMotif --quantMode GeneCounts) and transcripts
967 were assembled using StringTie ⁶¹ (version 2.0.6; parameters: -e) with GENCODE annotation
968 (VM19). For the repeat expression quantification, reads were re-aligned with additional parameters
969 '--outFilterMultimapNmax 50'.

970

971 TT-SLAM-Seq processing

972 Raw reads were trimmed by quality, Illumina adapter content and poly-A content analogous to the
973 RNAseq samples and aligned with STAR with parameters '--outFilterMultimapNmax 50 --
974 outReadsUnmapped Fastx' to the SILVA database ⁶² (download: March 6, 2020) in order to
975 remove rRNA content. Unaligned reads were afterwards reverse-complemented using the seqtk
976 'seq' command (<https://github.com/lh3/seqtk>, version 1.3-r106; parameters: -r). Reverse-
977 complemented reads were processed using SLAM-DUNK ⁶³ with the 'all' command (version
978 0.4.1; parameters: -rl 100 -5 0) with the GENCODE gene annotation (VM19) as '-b' option. Reads
979 with a 'T>C' conversion representing nascent transcription were filtered from the BAM files using
980 alleyoop (provided together with SLAM-DUNK) with the 'read-separator' command. Counts per
981 gene were quantified based on the 'T>C'-converted reads using htseq-count (version 0.11.4;
982 parameters: --stranded=yes, --nonunique=all) ⁶⁴. FPKM values were calculated based on the
983 resulting counts. For genome-wide coverage tracks, technical replicates were merged using
984 samtools 'merge' ⁶⁵. Coverage tracks for single and merged replicates were obtained using
985 deepTools bamCoverage ⁶⁵ (version: 3.4.3; parameters: --normalizeUsing CPM) separately for the
986 forward and reverse strand based on the 'T>C'-converted reads.

987

988 Public ChIP-Seq data

989 Fastq files of public ChIP-Seq data for H3K27Ac⁶⁶, H3K9me3²¹, HP1 α ²², TRIM28²¹, NANOG
990⁴⁰, OCT4⁴⁰ and SOX2⁴⁰ were downloaded from GEO ([Supplementary Table 1c](#)).

991

992 ChIP-Seq processing

993 Raw reads of treatment and input samples were subjected to adapter and quality trimming with
994 cutadapt (version 2.4; parameters: --nextseq-trim 20 --overlap 5 --minimum-length 25 --adapter
995 AGATCGGAAGAGC -A AGATCGGAAGAGC). Reads were aligned separately to the mouse
996 genome (mm10) and to the fly genome (*D. Melanogaster*, dm6) using BWA⁶⁷ with the ‘mem’
997 command (version 0.7.17, default parameters). A sorted BAM file was obtained and indexed using
998 samtools with the ‘sort’ and ‘index’ commands (version 1.10). Duplicate reads were identified and
999 removed using GATK⁶⁸ (version 4.1.4.1) with the ‘MarkDuplicates’ command and default
1000 parameters. Technical replicates of treatment and input samples were merged respectively using
1001 samtools ‘merge’. Peaks were called with reads aligning to the mouse genome only using MACS2
1002⁶⁹ ‘callpeak’ (version 2.1.2; parameters --bdg --SPMR) using the input samples as control samples.
1003 For H3K9me3 only, the ‘--broad’ option was used. Genome-wide coverage tracks for single and
1004 merged replicates normalized by library size were computed using deepTools bamCoverage
1005 (parameters: --normalizeUsing CPM --extendReads) and in addition normalized by the spike-in
1006 factor obtained from the reads aligning to the *Drosophila* genome as described⁵⁵.

1007

1008 Publicly available paired-end ChIP-Seq data (HP1 α) were processed as described above except
1009 spike-in and input normalization.

1010

1011 Publicly available single-end ChIP-Seq data (H3K9me3, TRIM28, H3K27ac, NANOG, OCT4,
1012 SOX2) were trimmed using cutadapt (version 2.4; parameters: --nextseq-trim 20 --overlap 5 --
1013 minimum-length 25 --adapter AGATCGGAAGAGC), and aligned and de-duplicated analogous
1014 to the paired-end data. In order to estimate the fragment size, only reads with a mapping quality
1015 of at least 15 were considered and used as input for spp⁷⁰ (version 1.2.2). All reads were then
1016 used to create coverage tracks using bamCoverage and to call peaks with MACS2 ‘callpeak’
1017 (version 2.1.2; parameters --bdg --SPMR --nomodel) with ‘--extsize’ set to the estimated
1018 fragment length divided by two and input samples used as control for H3K27ac, NANOG, OCT4
1019 and SOX2. For H3K9me3 only, the ‘--broad’ and ‘--nolambda’ options were used.

1020

1021 Enhancer and super-enhancer annotation

1022 The annotation of super-enhancers, enhancers and enhancer constituents was taken from Whyte et
1023 al.⁷¹. Coordinates were lifted from mm9 to mm10 using UCSC liftOver. These coordinates were
1024 used throughout this study for all enhancer-associated analyses ([Supplementary Table 2](#)).

1025

1026 Detection of eRNA expression and preparation of TT-SLAM-Seq histograms

1027 TT-SLAM-Seq signal was quantified at typical enhancer and SE constituents. Enhancers within
1028 3kb of TSS were excluded and intragenic enhancers were only considered on opposing strand
1029 relative to genes (GENCODE VM19, excluding “bidirectional_promoter_lncRNA”) to measure
1030 eRNA without interference from gene transcription. Gene coordinates were extended for 10kb
1031 from transcription termination site to prevent overlap of transcriptional readthrough signal. The
1032 detection of eRNA was performed at 2 kb regions centered by the constituent coordinates. TT-
1033 SLAM-Seq counts were quantified from .bam files with htseq-count (parameters: --stranded = yes,
1034 --nonunique = all). Differential expression analysis was performed on enhancer elements with
1035 DEseq2⁷² (parameters: test="LRT", reduced=~1) and excluding regions with less than 10 counts
1036 across samples. For visualizing fold changes, regions with low eRNA expression (FPKM < 1)
1037 were excluded ([Fig. 1h](#)).

1038

1039 Quantifications for eRNA histograms were done with HOMER software⁷³ (version 4.10) and only
1040 intergenic enhancers were considered. Reads from .bam files were prepared for quantifications
1041 with ‘makeTagDirectory’, and histograms for enhancer and SE constituents were prepared with
1042 ‘annotatePeaks.pl’ (parameters: -size 4000, -hist 20) and metagene plots for SEs with
1043 ‘makeMetaGeneProfile.pl’ (parameters: -min 500, -size 4000). Histograms were smoothed by
1044 taking a rolling mean with window size 5 before plotting.

1045

1046 To visualize TT-SLAM-Seq signal across genes, protein-coding genes were considered and
1047 metagene plot was prepared using ‘makeMetaGeneProfile.pl’ after removing outliers (FPKM <0.5
1048 or >100). Histograms were smoothed by taking a rolling mean with window size 3 before
1049 plotting ([Extended Data Fig. 3c](#)).

1050

1051 Differential gene expression analysis

1052 For the differential gene expression analysis only protein coding genes were considered.
1053 Differential expression for RNAseq and TT-SLAM-Seq samples was measured using DESeq2
1054 (parameters: test="LRT", reduced=~1) based on the raw counts per gene considering all time
1055 points per experiment type in one design. Only genes with at least 10 reads across all samples of
1056 the same experiment type were considered for the analysis. Genes with an absolute log₂ fold
1057 change greater than 1 in comparison to the DMSO control and an adjusted p-value of less than
1058 0.05 were termed differentially expressed per time point. Lowly expressed genes across all time
1059 points (average TPM across all RNAseq samples of less than 0.5 or average FPKM across all TT-
1060 SLAM-Seq samples of less than 0.25) were excluded from the analysis.

1061

1062 Gene set enrichment (GSEA) analysis

1063 GSEA was performed to test if super-enhancer (SE) associated genes were overrepresented in the
1064 sets of TT-SLAM-Seq differentially regulated genes. All protein-coding genes were ranked based
1065 on log₂ fold change. To prepare a gene set for the GSEA, Refseq IDs of SE-associated genes
1066 obtained from ⁷¹ were converted to (version free) Ensembl gene IDs using biomaRt R package ⁷⁴.
1067 GSEA was run with the fgsea R package ⁷⁵ using 100000 permutations ([Extended Data Fig. 5d](#)).

1068

1069 Retrotransposon element definition

1070 The genome-wide retrotransposon annotation of LTR, LINE and SINE elements was downloaded
1071 from Repbase ⁷⁶. Based on the Repbase classification system, we used the element annotation as
1072 LTR, LINE or SINE as the retrotransposon classes. Retrotransposon families considered in this
1073 study were L1 and L2 elements (LINE), ERV1, ERV3, ERVK, ERVL and MALR (LTR), as well
1074 as Alu, B2, B4 and MIR elements (SINE). Repeat subfamilies used in this study were subdivided
1075 into IAP, MMERVK and MMETn (ERVK) elements. IAPs and MMERVKs consist of multiple
1076 different subfamilies as annotated by Repbase ([Extended Data Fig. 1a, 4a](#)) which we summarized
1077 under these broader terms. The classification is consistent with retrotransposon classification
1078 described in previous studies ^{1,77,78}.

1079

1080 Full length retrotransposons were defined based on the Repbase repeat annotation. For full length
1081 ERVK elements, we required the element to consist of an inner part with two flanking LTRs. First,

1082 elements annotated as inner parts (containing the keyword ‘int’) were merged if they belonged to
1083 the same subfamily and were located within maximal 200 base pairs of each other. Second, only
1084 the merged inner parts with an annotated ERVK LTR within a distance of at most 50 base pairs on
1085 each side were selected as full length element candidates. For IAPs specifically only LTRs were
1086 considered that belonged to an IAP subfamily. No size restrictions were applied on the inner parts
1087 or LTRs which could lead to potential false positive candidates that are too truncated to be able to
1088 be transcribed but on the other hand provides an unbiased definition of full length repeat elements.
1089 The subfamily per element was defined based on the inner part.

1090

1091 Inner parts flanked by only one LTR were termed half length elements. LTRs without an inner part
1092 were termed solo LTRs.

1093

1094 In order to provide a broad overview of potential full length L1 elements only annotated elements
1095 with a size of more than 6 kb were shown.

1096

1097 The genomic co-ordinates of retrotransposons are listed in [Supplementary Table 2a-e](#).

1098

1099 Mappability

1100 The genome-wide mappability was calculated using GenMap⁷⁹ (parameters: -K 100 -E 0 -t -w -
1101 bg) with the mouse genome (mm10) as input ([Extended Data Fig. 1c-g](#)).

1102

1103 ChIP-Seq enrichment analysis

1104 Bigwig tracks of ChIP-Seq signal were imported into R with the package rtracklayer⁸⁰. Enriched
1105 heatmaps and metaprofile plots of ChIP-Seq signal were generated using the R package
1106 EnrichedHeatmap⁸¹. For this purpose, the signal was normalized to genomic features using the
1107 function ‘normalizeToMatrix’ (parameters: extend = c(2000, 2000), mean_mode = “w0”, w = 50,
1108 target_ratio = 0.25). The resulting data matrix was visualized using the function
1109 ‘EnrichedHeatmap’.

1110

1111 Hi-C data processing and analysis

1112 Raw reads were trimmed for adapters and quality as described above. Reads were further trimmed
1113 at MboI restriction site using cutadapt (version 2.4; parameters: -a GATC, --minimum-length 25)
1114 and separately aligned to the mouse genome (mm10) using BWA⁶⁷ ‘mem’ (version 0.7.17, default
1115 parameters). Replicates were processed individually and then merged with samtools ‘merge’⁶⁵.
1116 Remainder of Hi-C data processing was performed with HOMER software⁷³ (version 4.10), unless
1117 specified otherwise. Paired-end reads were matched and prepared for analysis with
1118 ‘makeTagDirectory’ and PCR duplicates were removed (parameters: -tbp 1). Reads were filtered
1119 to remove continuous genomic fragments, re-ligation events, self-ligations and tags from regions
1120 with unusually high tag density while keeping only paired-end reads where both reads have a MboI
1121 restriction site within the fragment length estimate 3’ to the read (parameters: -removePEbg -
1122 restrictionSite GATC -both -removeSelfLigation -removeSpikes 10000 5).

1123

1124 Analysis of compartments was performed with HOMER ‘runHiCpca.pl’ using resolution of 25 kb,
1125 50 kb analysis window and using H3K27Ac peaks to assign active (A) and inactive (B)
1126 compartments. Hi-C matrices were prepared for visualization with ‘analyzeHiC’ by normalizing
1127 counts to interactions per hundred square kilobases per billion (default) or displaying log2
1128 observed/expected counts normalized for interaction distance (parameters: -distNorm).
1129 Resolutions used were 150 kb for whole chromosome view ([Extended Data Fig. 10a](#)), 150kb
1130 resolution and 300 kb ‘window’ for region chr12:3,600,000-35,800,000 ([Extended Data Fig. 10b,](#)
1131 [left](#)) and in displaying differential (dTAG-13 - DMSO) of observed/expected matrix ([Extended](#)
1132 [Data Fig. 10b, right](#)). Images were prepared with Treeview 3.0

1133

1134 To perform pile-up analysis from ERV-gene and ERV-super-enhancer contacts, HOMER
1135 formatted Hi-C data was converted first to .hic format with ‘tagDir2hicFile.pl’ and then to .cool
1136 format with ‘hic2cool convert’ (version 0.8.3). Pile-up analysis was performed with ‘coolpup.py’
1137 software⁸² using Knight-Ruiz balanced matrices with 50 kb resolution and analyzing all cis
1138 interactions between ERVs and super-enhancers and between ERVs and protein coding genes,
1139 excluding genes with low expression (FPKM < 0.25 across TT-SLAM-Seq samples).

1140

1141 Motif enrichment

1142 Enrichment of motifs was calculated using ame (version 5.3.0, default parameters)⁸³. The
1143 sequences of 5' full length IAP LTRs and full length IAP inner parts were analyzed separately
1144 using the sequences of super-enhancer constituents as control ([Extended Data Fig. 8a](#)). In [Extended](#)
1145 [Data Fig. 8a.](#), the top TFs whose motifs show enrichment in the IAP LTRs or inner parts are shown.
1146 Also displayed is the expression level of the TFs calculated from the RNA-Seq data. For further
1147 functional tests, NFY was selected as its motif is highly enriched in IAPs, and it is expressed above
1148 50 TPM in mESCs.

1149

1150 scRNA-seq processing

1151 Fastq files for the wild-type time points E6.5 and E7.0 were downloaded from GEO
1152 ([Supplementary Table 1c](#))⁸⁴. For the wild-type time point E5.5 and the Trim28 KO, raw reads
1153 (fastq) were generated using Cell Ranger [[https://support.10xgenomics.com/single-cell-gene-](https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest)
1154 [expression/software/downloads/latest](https://support.10xgenomics.com/single-cell-gene-expression/software/downloads/latest)] (version 4) from 10x Genomics Inc. with the command
1155 'cellranger mkfastq'. Reads from all time points were aligned against the mouse genome (mm10),
1156 and barcodes and UMIs were counted using 'cellranger count'. Multiple sequencing runs were
1157 combined using 'cellranger aggr'.

1158

1159 Genotyping

1160 Genotyping was performed as described⁴². Briefly, samples were aligned against a hybrid mouse
1161 assembly (mm10 with positions of SNPs with the CAST/Eij strain masked as 'N' using SNPsplit
1162⁸⁵ using STAR (parameters: --outSAMattributes NH HI NM MD). Reads were sorted by reference
1163 genome using SNPsplit. SNPs identified in⁴² to be covered by reads from both genomic
1164 backgrounds were used to determine the allele composition for each cell. Individual cells were
1165 then assigned to embryos using the autosomal distribution of CAST/Eij SNPs. In order to
1166 determine embryo sex, marker genes *Xist*, *Erdr1*, *Ddx3y* and *Eif2s3y* were used to evaluate X and
1167 Y chromosome transcription based on the counts produced by Cell Ranger. Embryos were
1168 determined to be female if they had a high fraction of cells expressing *Xist*, while embryos with a
1169 high fraction of cells expressing *Erdr1*, *Ddx3y* and *Eif2s3y* were determined to be male. Cells that
1170 could not confidently be assigned to an embryo were discarded from the analysis.

1171

1172 Wild-type reference

1173 In order to define clusters of cells for the wild-type embryos, the R package Seurat ⁸⁶ was used.
1174 For each time point (E5.5, E6.5 and E7.0), the 3000 most variable genes were detected across all
1175 cells and embryos. All time points were integrated using the functions ‘FindIntegrationAnchors’
1176 and ‘IntegrateData’ (parameters: dims = 1:20). The combined wild-type time points were log2-
1177 normalized (‘NormalizeData’) and scaled while accounting for potential bias from cell cycle or
1178 mitochondrial gene counts using the function ‘ScaleData’ with parameters ‘vars.to.regress =
1179 c(‘percent.mt’, ‘S.Score’, ‘G2M.Score’)’. A UMAP was used to represent the cells in two dimensions
1180 using the function ‘RunUMAP’ (parameters: reduction = ‘pca’, dims = 1:20) based on the PCA
1181 computed by the function ‘RunPCA’ (parameters: npcs = 30). Six clusters of cells were identified
1182 using the functions ‘FindNeighbors’ (parameters: reduction = ‘pca’, dims = 1:20) and
1183 ‘FindClusters’ (parameters: resolution = 0.1). Marker genes per cluster were identified with the
1184 ‘FindAllMarkers’ function (parameters: only.pos = TRUE, min.pct = 0.25, logfc.threshold = 0.25).
1185 Based on the detected marker genes per cluster and literature-based markers of cell states we
1186 assigned clusters to the following cell states: epiblast, primitive streak, extraembryonic ectoderm
1187 (ExE)/trophoblast, visceral endoderm, mesoderm and parietal endoderm ([Supplementary Table 6](#)).
1188 The heatmap of marker genes per cell state was generated based on the z-score transformed log2-
1189 normalized counts using the function ‘DoHeatmap’ ([Extended Data Fig. 16e](#)).

1190

1191 Knockout assignment

1192 The E6.5 TRIM28 knockout expression data were log2-normalized analogous to the wild-type
1193 time points and transferred to the combined wild-type reference using the functions
1194 ‘FindTransferAnchors’ (parameters: dims = 1:30) and ‘TransferData’ (parameters: dims = 1:30)
1195 based on the cell states identified in the wild-type. Wild-type and knockout samples were
1196 integrated using ‘FindIntegrationAnchors’ and ‘IntegrateData’ (parameters: dims = 1:20, k.filter =
1197 50). Analogous to the wild-type reference, the combined dataset was scaled and a UMAP was used
1198 in order to represent the data in two dimensions (same parameters for all functions as for the wild-
1199 type reference).

1200

1201 Cell state proportions

1202 Per embryo, the proportion of a cell state was computed as the number of cells assigned to a cell
1203 state divided by the total number of cells assigned to the respective embryo. Per time point, cell

1204 state proportions were represented by the median of proportions of the respective cell state across
1205 all embryos of a developmental time point (Fig. 5e, Extended Data Fig. 17a-b).

1206

1207 RNA velocity

1208 RNA velocity was computed using velocity⁸⁷, visualized using scanpy⁸⁸, and projected on the
1209 wild-type reference UMAP (Extended Data Fig. 16d).

1210

1211 Retrotransposon expression quantification

1212 Global repeat expression quantification from RNAseq, TT-SLAM-Seq and scRNA-seq (Fig. 1e,
1213 Extended Data Fig. 4b-e) was carried out as described⁴². Briefly, in order to estimate the
1214 expression for each retrotransposon subfamily without bias due to gene expression, only reads not
1215 overlapping any gene were considered for the analysis. Reads overlapping splice sites as well as
1216 reads with a high poly-A content were removed. The remaining reads were counted per subfamily
1217 only if they aligned uniquely or multiple times to elements of the same subfamily. Here, any
1218 annotated element of a specific subfamily from Repbase was considered independent of our full
1219 length ERVK annotations. Reads aligning to multiple elements were only counted once. For
1220 scRNA-seq samples, reads were counted per subfamily, sample and cell state. The number of reads
1221 per subfamily were normalized by library size for RNAseq and TT-SLAM-Seq samples, and
1222 normalized by reads aligning to genes and repeats for scRNA-seq samples. Fold changes were
1223 calculated with respect to the DMSO or wild-type samples.

1224

1225 Pluripotency and differentiation marker quantification

1226 For the pluripotency and differentiation marker genes, TPMs were z-score transformed and
1227 visualized using the R package and function pheatmap [Kolde (2019) pheatmap: Pretty Heatmaps.
1228 R package version 1.0.12. <https://CRAN.R-project.org/package=pheatmap>] (Extended Data Fig.
1229 19b-c).

1230

1231 Statistical tests

1232 The statistical significance of the difference of IAP expression between DMSO control and dTAG
1233 time points for TT-SLAM-Seq and RNAseq was calculated using an unpaired two-sided t-test (Fig.
1234 1e). The significance for the difference in eRNA expression after 24h dTAG treatment (Fig. 1h)

1235 was calculated with one-sample t-test. Statistical significance of differences in fold changes (vs.
1236 DMSO) in control vs. 1.6-hexanediol -treated cells was estimated with unpaired two-sided t-test
1237 ([Extended Data Fig. 7e](#)). All other tests are described in the figure legends.

1238

1239 Definition of boxplot elements


1240 [Fig. 1h](#): Elements depicted in boxplot: middle line, median; box limits, upper and lower quartiles;
1241 whiskers, 1.5x interquartile range.

1242 [Fig. 5d](#): Elements depicted in Scatter dot plot: middle line, mean; scatter limits, upper and lower
1243 range.

1244 [Fig. 3e, 3f, 3g, 3i, Extended Data Fig. 12c, 12e, 12j, 13b](#): Elements depicted in boxplots: middle
1245 line, median; box limits, upper and lower quartile; whiskers, 1.5x interquartile range.

1246 [Extended Data Fig 6b, 14c](#): Elements depicted in dot plots: middle line, mean; whiskers, standard
1247 deviation; points, all data points.

Extended Data Fig. 1




1251 **Extended Data Fig. 1. TRIM28 occupies ERVs but not enhancers and promoters in mESCs**

1252 **a.** Classes of retrotransposons in the mouse

1253 **b.** (top) Model of TRIM28/HP1 α pathway and its major regulators at endogenous retroviruses
1254 (ERVs). KRAB-ZFP: KRAB-Zinc Finger Protein, TRIM28: Tripartite motif -containing protein
1255 28, HP1 α : heterochromatin protein 1 α . (bottom) Model of enhancers. Enhancers are bound by
1256 transcription factors (TFs) that recruit the Mediator complex and RNA Polymerase II (RNAPII).

1257 **c-j.** Heatmap representation of ChIP-seq read densities of the indicated factors within a 2kb
1258 window around the indicated genomic features. The genomic features (the middle part of the
1259 plot) were length normalized. Meta-analyses of the mean binding profile of the indicated factors
1260 are displayed above the heatmaps. Enhancers in mESCs are bound by the OCT4, SOX2,
1261 NANOG TFs, and are devoid of components of the TRIM28/HP1 α pathway that are bound at
1262 ERVs. For transposable elements, the mappability information is displayed on the right. Rpm:
1263 reads per million.

Extended Data Fig. 2



1264

1265 Extended Data Fig. 2. Extended characterization of TRIM28-FKBP ESCs

1266 **a.** Scheme of FKBP knock-in strategy at the *Trim28* locus.


1267 **b.** Western blot validation of the FKBP degron tag and its ability to degrade TRIM28. Washout
1268 of the dTAG-13 ligand (24h) indicates reversibility of degradation. Actin is shown as the loading
1269 control.

1270 **c.** Mass spectrometry analysis of protein levels after 24h of dTAG-13 treatment. Every dot
1271 corresponds to a quantified protein. The degradation appears highly selective for TRIM28.

1272 **d.** Scheme of the SSEA-1 staining experiments. SSEA-1 is a marker of pluripotent cells.
1273 Withdrawal of LIF in the cell culture medium leads to differentiation, and is included as a
1274 control.

1275 **e.** 24h of dTAG-13 treatment does not substantially change the fraction of cells expressing the
1276 SSEA-1 pluripotency marker. Displayed are representative images of SSEA-1-Cy5
1277 immunofluorescence experiments. Scale bars: 50µm.

Extended Data Fig. 3



1278

1279 Extended Data Fig. 3. TT-SLAM-Seq detects nascent transcription

1280 **a.** Schematic overview of the TT-SLAM-Seq experimental and analytical procedure.

1281 **b.** TT-SLAM-Seq and H3K27Ac ChIP-Seq browser tracks at the *KLF4* super-enhancer locus.

1282 Rpm: reads per million. Co-ordinates are mm10 genome assembly co-ordinates.

1283 **c.** TT-SLAM-Seq detects nascent transcription at genes, enhancers and super-enhancers.


1284 Displayed are meta representations of TT-SLAM-Seq read densities at genes, super-enhancers,

1285 constituent enhancers of super-enhancers, and enhancers in mESCs. Enhancers include all

1286 constituent enhancers of super-enhancers and typical enhancers. The genomic features at genes

1287 and super-enhancers were length normalized.

Extended Data Fig. 4



1288

1289 **Extended Data Fig. 4. Retrotransposon de-repression in TRIM28-degraded ESCs**

1290 **a.** Classes of retrotransposons in the mouse.

1291 **b.** Transcript levels of ERVs, LINEs and SINEs detected with TT-SLAM-Seq and RNA-Seq

1292 upon dTAG-13 treatment in mESCs. Values are normalized to the levels detected at 0h.

1293 **c.** Transcript levels of ERV (sub)classes detected with TT-SLAM-Seq and RNA-Seq upon
1294 dTAG-13 treatment in mESCs. Values are normalized to the levels detected at 0h.


1295 **d.** Transcript levels of IAP subfamilies detected with TT-SLAM-Seq and RNA-Seq upon dTAG-
1296 13 treatment in mESCs. Values are normalized to the levels detected at 0h.

1297 **e.** Transcript levels of the indicated ERV taxa detected with TT-SLAM-Seq and RNA-Seq upon
1298 dTAG-13 treatment in mESCs. Values are normalized to the levels detected at 0h.

1299 **f.** qRT-PCR analysis of IAPez RNA levels upon dTAG-13 treatment in mESCs. Values are
1300 normalized to the levels detected at 0h. ****: $P < 10^{-4}$, *: $P < 0.05$ (t test).

1301 **g.** Reduced H3K9me3 at IAPs, MMERVKs and MMETns in dTAG-13 treated (24h) mESCs.
1302 Displayed are heatmap representations of H3K9me3 ChIP-seq read densities within a 2kb
1303 window around the indicated genomic features. The genomic features (the middle part of the
1304 plot) were length normalized. Meta-analyses of the mean binding profile of the indicated factors
1305 are displayed above the heatmaps. Rpm: reads per million.

Extended Data Fig. 5



1306

1307 Extended Data Fig. 5. Reduction of super-enhancer transcription and the pluripotency 1308 circuit in TRIM28-degraded mESCs


1309 **a.** Acute reduction of transcription at the *MiR290-295* super-enhancer locus upon TRIM28-
1310 degradation. Displayed are genome browser tracks of ChIP-Seq data (H3K27Ac, OCT4, SOX2,
1311 NANOG) in control mESCs, and TT-SLAM-Seq data upon 0h, 2h, 6h and 24h dTAG-13
1312 treatment at the *MiR290-295* locus. Rpm: reads per million. Co-ordinates are mm10 genome
1313 assembly co-ordinates.

1314 **b.** Acute reduction of transcription at the *Mycn* super-enhancer locus upon TRIM28-degradation.
1315 Displayed are genome browser tracks of ChIP-Seq data (H3K27Ac, OCT4, SOX2, NANOG) in
1316 control mESCs, and TT-SLAM-Seq data upon 0h, 2h, 6h and 24h dTAG-13 treatment at the
1317 *Mycn* locus. Rpm: reads per million. Co-ordinates are mm10 genome assembly co-ordinates.

1318 **c.** qRT-PCR validation of the TT-SLAM-Seq data at the *MiR290-295* and *Klf4* loci. Displayed
1319 are transcript levels after the indicated duration of dTAG-13 treatment. Values are displayed as
1320 mean \pm -SD from three independent experiments, and are normalized to the level at 0h. P values
1321 are from two-tailed t tests. ****: $P < 10^{-4}$, ***: $P < 10^{-3}$, **: $P < 10^{-2}$, *: $P < 0.05$

1322 **d.** Genes downregulated after 24h dTAG-13 treatment are enriched for super-enhancer
1323 associated genes. Displayed is a Gene Set Enrichment Analysis (GSEA). Genes are ranked
1324 according to their fold change in transcription (TT-SLAM-Seq) after 24h dTAG-13 treatment.
1325 Genes associated a super-enhancer are marked with a black tick mark. Some of the genes
1326 implicated in the control of pluripotency are highlighted.

Extended Data Fig. 6




1327

1328 Extended Data Fig. 6. Loss of SE-association with RNAPII puncta at the *Mir290-295* super- 1329 enhancer

1330 **a.** Co-localization between the nascent RNA of *Mir290-295* and RNAPII puncta in mESCs. The
1331 co-localization is lost upon TRIM28-degradation. Displayed are separate images of the RNA-
1332 FISH and IF signal, and an image of the merged channels. The nuclear periphery determined by
1333 DAPI staining (not shown) is highlighted as a white contour. Also shown are averaged signal of
1334 either RNA FISH or RNAPII IF centered on the *Mir290-295* FISH foci or randomly selected
1335 nuclear positions. These data were collected as an independent experimental verification of data
1336 displayed in Fig. 1i. Scale bars: 2.5 μ m.

1337 **b.** dTAG-13 treatment leads to reduced RNAPII immunofluorescence signal at *Mir290-295*
1338 FISH foci, but does not change overall RNAPII levels. (left) quantification of RNAPII IF
1339 intensities at the *Mir290-295* FISH foci detected in the cells used in Fig. 1i. (center)
1340 quantification of RNAPII mean fluorescence intensity in the cells used in Fig. 1i. (right)
1341 quantification of the number of RNAPII puncta in the cells used in Fig. 1i. P values are from
1342 Mann Whitney tests n.s.: not significant.

Extended Data Fig. 7



1344 **Extended Data Fig. 7. Condensate hijacking additional data**

1345 **a-b.** Co-localization between the *IAP* RNA and **(a)** RNAPII puncta, **(b)** MED23 puncta in
1346 TRIM28-degraded mESCs. Displayed are separate images of the RNA-FISH and IF signal, and
1347 an image of the merged channels. The nuclear periphery determined by DAPI staining (not
1348 shown) is highlighted as a white contour. The zoom column displays the region of the images
1349 highlighted in a yellow box zoomed in for greater detail. After 24h dTAG-13 treatment, small
1350 nuclear puncta appear, after 48h of dTAG-13 treatment large nuclear foci are visible. Scale bars:
1351 2.5 μ m.

1352 **c.** Scheme of the 1-6 hexanediol (1-6 HD) treatment experiments.

1353 **d.** Representative images of RNAPII immunofluorescence in control and 1-6 HD-treated cells. 1-
1354 6 HD partially dissolved the punctate localization of RNAPII. Scale bars: 5 μ m.


1355 **e.** Transcription of the nascent *Cthrc1* RNA is reduced by 30min 1% 1-6 hexanediol-treatment in
1356 TRIM28-degraded cells. The bar plots show qRT-PCR data as fold change normalized to the
1357 DMSO control. Note that the *IAP* RNA does not contain introns, thus the *IAP* RNA qRT-PCR
1358 detects the steady state pool of *IAP* RNAs. P values are from two-tailed t tests.

1359 **f.** (left) The *Cthrc1* locus, highlighting the three ERVs that are deleted in the ERV TKO mESC
1360 line. TRIM28 ChIP-Seq data is shown above the gene models. (right) Genotyping PCR of the
1361 ERV TKO cell line.


1362 **g.** Absence of *Cthrc1* induction in the ERV TKO cell line upon TRIM28- degradation. The bar
1363 plots show qRT-PCR data for *IAP* RNA, *Cthrc1* mRNA and the *Pri-MiR-290-295* transcript.
1364 Data are from biological duplicate experiments. P values are from two-tailed t tests. ****: $P < 10^{-4}$

Extended Data Fig. 8


a




b



c



d



1365

1366 **Extended Data Fig. 8. Additional characterization NFYA and NRF1**

1367 **a.** The sequence of IAPs is enriched for various TF binding motifs, including the motif of NFYA.
 1368 Top: schematic of an IAP element; Bottom: motif images, adjusted P-values and motif IDs, and
 1369 the expression level of the TF in mESC RNA-Seq data. Displayed are the top scoring motifs
 1370 based on adjusted P-value. Motifs were filtered for redundancy.


1371 **b.** The RNAPII IF signal at *Cthrc1* FISH foci is higher than the average nuclear signal.
 1372 Quantification of the RNAPII IF intensity at *Cthrc1* FISH foci and nuclei in the cells analyzed in
 1373 Fig. 2f is showed. P value is from a Mann Whitney test.

1374 **c.** The NFYA IF signal at *Cthrc1* FISH foci is higher than the average nuclear signal.
 1375 Quantification of the NFYA IF intensity at *Cthrc1* FISH foci and nuclei in the cells analyzed in
 1376 Fig. 2g is showed. P value is from a Mann Whitney test.


1377 **d.** NRF1 puncta do not co-localize with the nascent RNA *Cthrc1* in TRIM28-degraded mESCs.
1378 Displayed are separate images of the RNA-FISH and IF signal, and an image of the merged
1379 channels. The nuclear periphery determined by DAPI staining (not shown) is highlighted as a
1380 white contour. Also shown are averaged signal of either RNA FISH or NRF1 IF centered on the
1381 *Cthrc1* FISH foci or randomly selected nuclear positions. Scale bars: 2.5 μ m.

Extended Data Fig. 9

a



b



1382

1383 **Extended Data Fig. 9. Reduced occupancy of transcription-associated factors at super-**
 1384 **enhancers and increased occupancy at ERVs in TRIM28-degraded mESCs**


1385 **a.** Genome browser tracks of ChIP-Seq data (H3K27Ac, RNAPII, MED23) in control mESCs

1386 and upon 24h dTAG-13 treatment at the *MiR290-295* locus. Rpm: reads per million.


1387 **b.** Heatmap and meta representations of H3K27Ac, MED23 and RNAPII ChIP-Seq read
1388 densities at IAP, MMERVK and MMETn ERVs in control (DMSO) and dTAG-13 (24h) treated
1389 mESCs. The mean read densities are displayed +/-2kb around the indicated elements. The
1390 genomic elements (the middle part of the meta plot) were length normalized.

Extended Data Fig. 10


a




b



c



d



1391

1392 **Extended Data Fig. 10. TRIM28-dagradaation leads to shift of ERVs from the inactive “B”**
 1393 **towards the active “A” compartment**


1394 **a.** TRIM28-degradation does not lead to major genome-wide changes in chromatin contacts.
1395 Displayed are the Hi-C interaction matrices for chromosome 12, and the Principal Component 1
1396 (PC1) of the normalized interaction matrix of the DMSO control and dTAG-treated samples.

1397 **b.** (left) Hi-C interaction matrices for chromosome 12, zoomed-in on an ERV cluster, and the
1398 Principal Component 1 (PC1) of the normalized interaction matrix of the DMSO control and
1399 dTAG-treated samples. (right) differential interaction matrix of the region shown in the left.

1400 **c.** TRIM28-degradation leads to shift of ERVs from the inactive “B” towards the active “A”
1401 compartment. Quantification of the mean compartment score (value of the PC1) of the indicated
1402 genomic regions. The values are displayed as the log₂ fold change between the PC1 value in the
1403 dTAG-treated sample normalized against the values in the DMSO control sample.

1404 **d.** Pile-up analysis of contacts between IAPs, MERVKs, MMETns and (top) transcribed genes or
1405 (bottom) super-enhancers (SEs) in wild type and TRIM28-degraded mESCs. The “all ERVs set”
1406 includes the combination of IAPs, MERVKs and MMETns.

Extended Data Fig. 11



1407

1408

1409 **Extended Data Fig. 11. Knockdown of ERV RNA rescues super-enhancer transcription in**
1410 **TRIM28-degraded cells**

1411 **a.** Schematic model of the experiment knocking down IAP, MMERVK10c, MMERKV9c and
1412 MMETn transcripts simultaneously with TRIM28 degradation (24h).

1413 **b.** qRT-PCR analysis of IAP, MMERVK10c, MMERKV9c, MMETn, *Cthrc1*, *MiR290-295*
1414 primary transcript, *MiR290-295* super-enhancer RNA, *Klf4* mRNA, *Klf4* super-enhancer RNA,
1415 *Fgf4* mRNA, *Fgf4* super-enhancer RNA. Note that the qPCR primers used for MMETn and
1416 MERVK9c elements fail to detect induction after dTAG-13 treatment, which is explained by
1417 these elements having degenerate genomic sequences. Nevertheless, the combined knockdown in
1418 part rescues the induction of *Cthrc1* and downregulation of super-enhancers and their associated
1419 genes in TRIM28-degraded cells. P values are from two-tailed t tests. *****: $P < 10^{-4}$, ***: $P < 10^{-3}$,
1420 **: $P < 10^{-2}$, *: $P < 0.05$

1421 **c.** Schematic model of the experiment knocking down IAP transcripts simultaneously with
1422 TRIM28 degradation (24h).


1423 **d.** IAP knockdown alone failed to rescue downregulation of super-enhancers and their associated
1424 transcripts The bar plots show qRT-PCR data as fold change normalized to the 0h control. P
1425 values are from two-tailed t tests. *****: $P < 10^{-4}$, ***: $P < 10^{-3}$, **: $P < 10^{-2}$, *: $P < 0.05$

1426 **e.** Schematic model of the experiment in which shRNAs targeting IAP, MMERVK10c,
1427 MMERKV9c and MMETn transcripts are induced for 24h of Dox treatment, and the cells are
1428 treated either with DMSO (yellow), dTAG-13 (orange) or with dTAG-13 and Dox (maroon) for
1429 additional 24h.

1430 **f.** Rescue of *Klf4* super-enhancer and primary transcript levels, and of *Fgf4* super-enhancer and
1431 primary transcript levels upon ERV RNA-knockdown in TRIM28-degraded cells. The bar plots
1432 show qRT-PCR data as fold change normalized to the Dox (24h) treatment control. P values are
1433 from two-tailed t tests. *****: $P < 10^{-4}$, ***: $P < 10^{-3}$, **: $P < 10^{-2}$, *: $P < 0.05$.

1434 **g.** Representative images of *IAP* RNA FISH in cells described in panels (e-f). Scale bar: 2.5 μ m.

Extended Data Fig. 12



1435

1436 **Extended Data Fig. 12. IAP RNA facilitates droplet formation of transcriptional activators**
 1437 **in vitro**

1438 **a.** IAP RNA facilitates RNAPII CTD droplet formation in vitro. Displayed are representative
 1439 images of droplet formation by purified RNAPII CTD-mCherry fusion proteins in the presence

1440 of in vitro transcribed IAP RNA fragments. As expected, fusion events between droplets were
1441 also observed. Scale bar: 10 μ m.

1442 **b.** IAP RNA facilitates MED1 IDR droplet formation in vitro. Displayed are representative
1443 images of droplet formation by purified MED1 IDR-mCherry fusion proteins in the presence of
1444 in vitro transcribed IAP RNA.

1445 **c.** Partitioning ratio of MED1 IDR-mCherry into droplets at the indicated IAP RNA
1446 concentrations. Every dot represents a detected droplet.

1447 **d.** *IAP* RNA is enriched within MED1 IDR droplets. Displayed are representative images of the
1448 enrichment of fluorescein-labeled *IAP* RNA in MED1 IDR-mCherry droplets.

1449 **e.** Quantification of the enrichment of fluorescein-labeled *IAP* RNA in MED1 IDR-mCherry
1450 droplets.

1451 **f.** Fluorescence recovery after photobleaching (FRAP) experiments of MED1 IDR droplets in the
1452 absence or presence of 50nM *IAP* RNA.

1453 **g.** (left) Schematic model of the heterotrimeric NFY transcription factor. (right) Graphs plotting
1454 intrinsic disorder in the NFYA, NFYB and NFYC proteins. The NFYC IDR cloned for
1455 subsequent experiments is highlighted with a blue bar.


1456 **h.** Concentration-dependent droplet formation by purified recombinant NFYC IDR-mEGFP.
1457 Scale bar: 10 μ m.

1458 **i.** The NFYC IDR forms heterotypic droplets with MED IDR in vitro. Displayed are
1459 representative images of droplet formation by purified NFYC IDR-mEGFP and MED1 IDR-
1460 mCherry fusion proteins. MED1 IDR-mCherry mixed with purified mGFP is included as a
1461 control. Scale bar: 10 μ m.


1462 **j.** Partitioning ratio of NFYC IDR-mEGFP or mEGFP in MED1 IDR-mCherry droplets. Every
1463 dot represents a detected droplet. P-value < 2.2*10⁻¹⁶ (Welch's t-test).

Extended Data Fig. 13

a



b



1464

1465 **Extended Data Fig. 13. Effects of various RNAs on MED1 IDR and HP α droplets in vitro**

1466 **a.** RNA facilitates MED IDR and droplet HP α formation in vitro. Displayed are representative


1467 images of droplet formation by purified (left) MED1 IDR-mEGFP fusion protein and (right)

1468 HP α -mCherry fusion protein in the presence of in vitro transcribed RNA fragments. Scale bar:

1469 10 μ m.

1470 **b.** Quantification of the partitioning of (left) MED1 IDR and (right) HPI α into droplets in the
1471 presence of the indicated RNA species. Values are normalized against the partition ratio at no
1472 RNA added.

Extended Data Fig. 14



1474 **Extended Data Fig. 14. Additional characterization of the OSKM/dTAG-13 experiments**

1475 **a.** Western blot validation of the FKBP degron tag and its ability to degrade TRIM28 in iPSCs.
1476 Washout of the dTAG-13 ligand (24h) indicates reversibility of degradation. Actin is shown as
1477 the loading control.

1478 **b.** Western blot validation of the OSKM ectopic expression in the iPSC line. HSP90 is shown as
1479 the loading control.

1480 **c.** dTAG-13 treatment leads to reduced RNAPII immunofluorescence signal at *MiR290-295*
1481 FISH foci which is rescued by OSKM ectopic expression, while overall RNAPII levels do not
1482 change. (top) Quantification of RNAPII mean fluorescence intensity in the cells used in Fig. 3f.
1483 (bottom) Quantification of RNAPII IF intensities at the *MiR290-295* FISH foci detected in the
1484 cells used in Fig. 3f. P value is from Mann Whitney test.

1485 **d.** TRIM28-degradation does not substantially alter the protein levels of subunits of RNAPII and
1486 Mediator complex. Displayed are mass spectrometry-detected protein abundance for three
1487 individual replicate samples after 0h, 24h, 48h, 72h and 96h dTAG-13 treatment of mESCs.
1488 RNAPII subunits are highlighted in green. Mediator complex subunits are highlighted in red.


1489 **e.** Elevated levels of *Klf4* super-enhancer transcript and *Klf4* nascent transcript in TRIM28-
1490 degraded iPSCs that ectopically express OSKM factors. The line plots show qRT-PCR data
1491 normalized to the 0h of dTAG-13 treatment. P values are from two-tailed t tests.

1492 **f.** Elevated levels of *Fgf4* super-enhancer transcript and *Fgf4* nascent transcript in TRIM28-
1493 degraded iPSCs that ectopically express OSKM factors. The line plots show qRT-PCR data
1494 normalized to the 0h of dTAG-13 treatment. P values are from two-tailed t tests.

1495 **g.** Elevated levels of *Oct4* super-enhancer transcript and *Oct4* nascent transcript in TRIM28-
1496 degraded iPSCs that ectopically express OSKM factors. The line plots show qRT-PCR data
1497 normalized to the 0h of dTAG-13 treatment. P values are from two-tailed t tests.

1498 **h.** Elevated levels of *Mycn* super-enhancer transcript and *Mycn* nascent transcript in TRIM28-
1499 degraded iPSCs that ectopically express OSKM factors. The line plots show qRT-PCR data
1500 normalized to the 0h of dTAG-13 treatment. P values are from two-tailed t tests.

Extended Data Fig. 15



1501

1502

1503 Extended Data Fig. 15. Simultaneous transcription of a high copy number of GFP
1504 transgenes compromises super-enhancer transcription


1505 **a.** Schematic model of the experiment mimicking ERV transcription. mESC lines harboring 15, 3
 1506 or 1 copies of a Piggyback transposon encoding a Dox-inducible GFP transgene and degradation
 1507 sensitive TRIM28-FKBP alleles were treated with Dox (to induce GFP expression) and/or
 1508 dTAG-13 (to induce TRIM28 degradation).

1509 **b.** qRT-PCR quantification of the copy number of GFP transgenes in the GPP (high), GFP (mid),
 1510 GFP (low) and control (i.e. parental) mESC cell lines.

1511 **c.** qRT-PCR quantification of GFP RNA and *Cthrc1* mRNA following the indicated treatments.
 1512 Data are from biological triplicate experiments. P value is from a two-tailed t test. ****: $P < 10^{-4}$

1513 **d.** Simultaneous transcription of a high copy number of GFP transgenes leads to a reduction of
 1514 transcription at the *Klf4* and *Fgf4* super-enhancers and their associated genes. The bar plots show
 1515 qRT-PCR data as fold change normalized to the DMSO control treatment. P values are from
 1516 two-tailed t tests. ****: $P < 10^{-4}$, ***: $P < 10^{-3}$.

Extended Data Fig. 16



1517

1518 **Extended Data Fig. 16. Reference cell state maps in early mouse embryos**

1519 **a.** Scheme of the zygotic CRISPR/Cas9 – scRNA-Seq platform.

1520 **b.** Immunofluorescence verification of TRIM28 KO. Representative images are shown, with the
 1521 number of embryos where the immunofluorescence confirmed the genotype per the total number
 1522 of embryos analyzed. Scale bars: 20µm.

1523 **c.** UMAP of wild type early mouse embryos spanning E5.5-E7.0 developmental window. The
1524 wild type cells used in scRNA-Seq experiments from E5.5, E6.5 and E7.0 developmental stages
1525 were included.


1526 **d.** RNA velocity map of wild type early mouse embryos spanning E5.5-E7.0 developmental
1527 window.

1528 **e.** Heatmap representation of the expression levels of marker genes of each cluster/cell state.

1529 **f.** Combined cell state map. The wild type cells and TRIM28 KO cells used in scRNA-Seq
1530 experiments were included.

1531 **g.** Elevated *IAP* expression in TRIM28 KO cells. (left) Wild type cells used in scRNA-Seq
1532 experiments from E5.5, E6.5 and E7.0 developmental stages are projected on the combined
1533 reference map, and are colored according to *IAP* expression. (right) TRIM28 KO E6.5 cells are
1534 projected on the combined reference map, and are colored according to *IAP* expression.

Extended Data Fig. 17



1535

1536 **Extended Data Fig. 17. Cell state proportions in individual embryos reveal depletion of**
 1537 **epiblast cells in E6.5 TRIM28 KO mouse embryos**


1538 **a.** (top) Cell state proportions in each embryo from the E5.5 (left), E6.5 (middle), and E7.0

1539 (right) developmental stages analyzed in scRNA-Seq experiments. (bottom) Cell state

1540 proportions in E6.5 TRIM28 KO embryo analyzed in scRNA-Seq experiments.

1541 **b.** Combined cell state proportions per embryonic stage.

Extended Data Fig. 18




1542

1543 Extended Data Fig. 18. Loss of pluripotency markers in TRIM28 KO blastocysts

1544 **a.** The cells in the inner part of TRIM28 KO blastocysts are populated by cells that express
1545 reduced levels of OCT4 and KLF4. Displayed are representative immunofluorescence images of
1546 OCT4 and KLF4 in E3.5 wild type and TRIM28 KO blastocysts. Nuclei are stained with DAPI.
1547 Scale bars: 20µm. Scale bars: 20µm.

1548 **b.** The cells in the inner part of TRIM28 KO blastocysts are populated by cells that express
1549 reduced levels of SOX2. Displayed are representative immunofluorescence images of SOX2 and
1550 in E3.5 wild type and TRIM28 KO blastocysts. Nuclei are counterstained with DAPI. Scale bars:
1551 20µm.

Extended Data Fig. 19



1552

1553 **Extended Data Fig. 19. Long term TRIM28 degradation induces differentiation markers in**
 1554 **ESCs**

1555 **a.** 96h of TRIM28 degradation leads to an increased fraction of cells with reduced expression of
 1556 the SSEA-1 pluripotency marker. Displayed are FACS profiles of cell populations treated for the
 1557 indicated times with dTAG-13.

1558 **b.** Upregulation of differentiation marker genes upon dTAG-13 treatment in mESCs. Displayed
 1559 is a heatmap representation of RNA-Seq read density (TPM) Z scores for the indicated genes.
 1560 The annotation on the right indicates whether a gene is identified as differentially expressed at
 1561 the indicated time points relative to the level at 0h.

1562 **c.** Upregulation of 2C marker genes upon dTAG-13 treatment in mESCs. Displayed is a heatmap
 1563 representation of RNA-Seq read density (TPM) Z scores for the indicated genes. The annotation
 1564 on the right indicates whether a gene is identified as differentially expressed at the indicated time
 1565 points relative to the level at 0h.

1566 **Supplementary Table Legends**

1567

1568 **Table S1. List of reagents and datasets**

1569 **a.** RNA FISH probes

1570 **b.** Primers used in the study

1571 **c.** GEO accession IDs of public data used in the study

1572

1573 **Table S2. Feature annotations**

1574 **a.** full length IAPs (coordinates in mm10 genome assembly coordinates)

1575 **b.** full length MMERVKs (coordinates in mm10 genome assembly coordinates)

1576 **c.** full length MMETns (coordinates in mm10 genome assembly coordinates)

1577 **d.** Full length LINEs (coordinates in mm10 genome assembly coordinates)

1578 **e.** All IAP LTRs (coordinates in mm10 genome assembly coordinates)

1579 **f.** mESC enhancers (OSN constituent enhancers) (coordinates in mm10 genome assembly
1580 coordinates)

1581 **g.** mESC super-enhancers (coordinates in mm10 genome assembly coordinates)

1582 **h.** mESC typical enhancer (coordinates in mm10 genome assembly coordinates)

1583

1584 **Table S3. Mass-spectrometry data**

1585 This table contains the mass spectrometry data used in [Extended Data Fig. 2c](#) and [14d](#).

1586

1587 **Table S4. TT-SLAM-Seq fold change data (genes)**

1588 This table contains the fold change values used in [Fig. 1g](#).

1589

1590 **Table S5. TT-SLAM-Seq fold change data (enhancers)**

1591 This table contains the fold change values used in [Fig. 1h](#).

1592

1593 **Table S6. Marker genes in scRNA-Seq clusters**

1594 This table contains information on the marker genes used to identify clusters in the scRNA-Seq
1595 data.

1596 **References**

1597

- 1598 1 Thompson, P. J., Macfarlan, T. S. & Lorincz, M. C. Long Terminal Repeats: From
 1599 Parasitic Elements to Building Blocks of the Transcriptional Regulatory Repertoire.
 1600 *Molecular cell* **62**, 766-776, doi:10.1016/j.molcel.2016.03.029 (2016).
- 1601 2 Grewal, S. I. & Jia, S. Heterochromatin revisited. *Nature reviews. Genetics* **8**, 35-46,
 1602 doi:10.1038/nrg2008 (2007).
- 1603 3 Cordaux, R. & Batzer, M. A. The impact of retrotransposons on human genome
 1604 evolution. *Nature reviews. Genetics* **10**, 691-703, doi:10.1038/nrg2640 (2009).
- 1605 4 Payer, L. M. & Burns, K. H. Transposable elements in human genetic disease. *Nature*
 1606 *reviews. Genetics* **20**, 760-772, doi:10.1038/s41576-019-0165-8 (2019).
- 1607 5 Rowe, H. M. & Trono, D. Dynamic control of endogenous retroviruses during
 1608 development. *Virology* **411**, 273-287, doi:10.1016/j.virol.2010.12.007 (2011).
- 1609 6 Wells, J. N. & Feschotte, C. A Field Guide to Eukaryotic Transposable Elements. *Annual*
 1610 *review of genetics* **54**, null, doi:10.1146/annurev-genet-040620-022145 (2020).
- 1611 7 Rowe, H. M. *et al.* KAP1 controls endogenous retroviruses in embryonic stem cells.
 1612 *Nature* **463**, 237-240, doi:10.1038/nature08674 (2010).
- 1613 8 Cammas, F. *et al.* Mice lacking the transcriptional corepressor TIF1beta are defective in
 1614 early postimplantation development. *Development* **127**, 2955-2963 (2000).
- 1615 9 Matsui, T. *et al.* Proviral silencing in embryonic stem cells requires the histone
 1616 methyltransferase ESET. *Nature* **464**, 927-931, doi:10.1038/nature08858 (2010).
- 1617 10 Hu, G. *et al.* A genome-wide RNAi screen identifies a new transcriptional module
 1618 required for self-renewal. *Genes & development* **23**, 837-848, doi:10.1101/gad.1769609
 1619 (2009).
- 1620 11 Xu, W. *et al.* METTL3 regulates heterochromatin in mouse embryonic stem cells. *Nature*
 1621 **591**, 317-321, doi:10.1038/s41586-021-03210-1 (2021).
- 1622 12 Chelmicki, T. *et al.* m(6)A RNA methylation regulates the fate of endogenous
 1623 retroviruses. *Nature* **591**, 312-316, doi:10.1038/s41586-020-03135-1 (2021).
- 1624 13 Liu, J. *et al.* The RNA m(6)A reader YTHDC1 silences retrotransposons and guards ES
 1625 cell identity. *Nature* **591**, 322-326, doi:10.1038/s41586-021-03313-9 (2021).
- 1626 14 Mouse Genome Sequencing, C. *et al.* Initial sequencing and comparative analysis of the
 1627 mouse genome. *Nature* **420**, 520-562, doi:10.1038/nature01262 (2002).
- 1628 15 Maksakova, I. A. *et al.* Retroviral elements and their hosts: insertional mutagenesis in the
 1629 mouse germ line. *PLoS genetics* **2**, e2, doi:10.1371/journal.pgen.0020002 (2006).
- 1630 16 Wolf, G. *et al.* KRAB-zinc finger protein gene expansion in response to active
 1631 retrotransposons in the murine lineage. *eLife* **9**, doi:10.7554/eLife.56337 (2020).
- 1632 17 Lachner, M., O'Carroll, D., Rea, S., Mechtler, K. & Jenuwein, T. Methylation of histone
 1633 H3 lysine 9 creates a binding site for HP1 proteins. *Nature* **410**, 116-120,
 1634 doi:10.1038/35065132 (2001).
- 1635 18 Wolf, G. *et al.* The KRAB zinc finger protein ZFP809 is required to initiate epigenetic
 1636 silencing of endogenous retroviruses. *Genes & development* **29**, 538-554,
 1637 doi:10.1101/gad.252767.114 (2015).
- 1638 19 Schultz, D. C., Ayyanathan, K., Negorev, D., Maul, G. G. & Rauscher, F. J., 3rd.
 1639 SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that

1640 contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger
 1641 proteins. *Genes & development* **16**, 919-932, doi:10.1101/gad.973302 (2002).
 1642 20 Yang, B. X. *et al.* Systematic identification of factors for provirus silencing in embryonic
 1643 stem cells. *Cell* **163**, 230-245, doi:10.1016/j.cell.2015.08.037 (2015).
 1644 21 Elsasser, S. J., Noh, K. M., Diaz, N., Allis, C. D. & Banaszynski, L. A. Histone H3.3 is
 1645 required for endogenous retroviral element silencing in embryonic stem cells. *Nature*
 1646 **522**, 240-244, doi:10.1038/nature14345 (2015).
 1647 22 Bulut-Karslioglu, A. *et al.* Suv39h-dependent H3K9me3 marks intact retrotransposons
 1648 and silences LINE elements in mouse embryonic stem cells. *Molecular cell* **55**, 277-290,
 1649 doi:10.1016/j.molcel.2014.05.029 (2014).
 1650 23 Macfarlan, T. S. *et al.* Embryonic stem cell potency fluctuates with endogenous retrovirus
 1651 activity. *Nature* **487**, 57-63, doi:10.1038/nature11244 (2012).
 1652 24 Rowe, H. M. *et al.* TRIM28 repression of retrotransposon-based enhancers is necessary
 1653 to preserve transcriptional dynamics in embryonic stem cells. *Genome research* **23**, 452-
 1654 461, doi:10.1101/gr.147678.112 (2013).
 1655 25 Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory evolution of innate immunity
 1656 through co-option of endogenous retroviruses. *Science* **351**, 1083-1087,
 1657 doi:10.1126/science.aad5497 (2016).
 1658 26 Nabet, B. *et al.* The dTAG system for immediate and target-specific protein degradation.
 1659 *Nat Chem Biol* **14**, 431-441, doi:10.1038/s41589-018-0021-8 (2018).
 1660 27 Reichholf, B. *et al.* Time-Resolved Small RNA Sequencing Unravels the Molecular
 1661 Principles of MicroRNA Homeostasis. *Molecular cell* **75**, 756-768 e757,
 1662 doi:10.1016/j.molcel.2019.06.018 (2019).
 1663 28 Muhar, M. *et al.* SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC
 1664 axis. *Science* **360**, 800-805, doi:10.1126/science.aao2793 (2018).
 1665 29 Schwalb, B. *et al.* TT-seq maps the human transient transcriptome. *Science* **352**, 1225-
 1666 1228, doi:10.1126/science.aad9841 (2016).
 1667 30 Boehning, M. *et al.* RNA polymerase II clustering through carboxy-terminal domain
 1668 phase separation. *Nature structural & molecular biology* **25**, 833-840,
 1669 doi:10.1038/s41594-018-0112-y (2018).
 1670 31 Sabari, B. R. *et al.* Coactivator condensation at super-enhancers links phase separation
 1671 and gene control. *Science*, doi:10.1126/science.aar3958 (2018).
 1672 32 Cho, W. K. *et al.* Mediator and RNA polymerase II clusters associate in transcription-
 1673 dependent condensates. *Science*, doi:10.1126/science.aar4199 (2018).
 1674 33 Guo, Y. E. *et al.* Pol II phosphorylation regulates a switch between transcriptional and
 1675 splicing condensates. *Nature* **572**, 543-548, doi:10.1038/s41586-019-1464-0 (2019).
 1676 34 Roden, C. & Gladfelter, A. S. RNA contributions to the form and function of
 1677 biomolecular condensates. *Nature reviews. Molecular cell biology*, doi:10.1038/s41580-
 1678 020-0264-6 (2020).
 1679 35 Henninger, J. E. *et al.* RNA-Mediated Feedback Control of Transcriptional Condensates.
 1680 *Cell* **184**, 207-225 e224, doi:10.1016/j.cell.2020.11.030 (2021).
 1681 36 Boija, A. *et al.* Transcription Factors Activate Genes through the Phase-Separation
 1682 Capacity of Their Activation Domains. *Cell* **175**, 1842-1855 e1816,
 1683 doi:10.1016/j.cell.2018.10.042 (2018).
 1684 37 Larson, A. G. *et al.* Liquid droplet formation by HP1alpha suggests a role for phase
 1685 separation in heterochromatin. *Nature* **547**, 236-240, doi:10.1038/nature22822 (2017).

1686 38 Huo, X. *et al.* The Nuclear Matrix Protein SAFB Cooperates with Major Satellite RNAs
1687 to Stabilize Heterochromatin Architecture Partially through Phase Separation. *Molecular*
1688 *cell* **77**, 368-383 e367, doi:10.1016/j.molcel.2019.10.001 (2020).

1689 39 Wernig, M. *et al.* A drug-inducible transgenic system for direct reprogramming of
1690 multiple somatic cell types. *Nature biotechnology* **26**, 916-924, doi:10.1038/nbt1483
1691 (2008).

1692 40 Whyte, W. A. *et al.* Master transcription factors and mediator establish super-enhancers at
1693 key cell identity genes. *Cell* **153**, 307-319, doi:10.1016/j.cell.2013.03.035 (2013).

1694 41 Konermann, S. *et al.* Genome-scale transcriptional activation by an engineered CRISPR-
1695 Cas9 complex. *Nature* **517**, 583-588, doi:10.1038/nature14136 (2015).

1696 42 Grosswendt, S. *et al.* Epigenetic regulator function through mouse gastrulation. *Nature*
1697 **584**, 102-108, doi:10.1038/s41586-020-2552-x (2020).

1698 43 Mitsui, K. *et al.* The homeoprotein Nanog is required for maintenance of pluripotency in
1699 mouse epiblast and ES cells. *Cell* **113**, 631-642, doi:10.1016/s0092-8674(03)00393-3
1700 (2003).

1701 44 Wang, J. *et al.* Primate-specific endogenous retrovirus-driven transcription defines naive-
1702 like stem cells. *Nature* **516**, 405-409, doi:10.1038/nature13804 (2014).

1703 45 Kunarso, G. *et al.* Transposable elements have rewired the core regulatory network of
1704 human embryonic stem cells. *Nature genetics* **42**, 631-634, doi:10.1038/ng.600 (2010).

1705 46 Quinodoz, S. A. *et al.* RNA promotes the formation of spatial compartments in the
1706 nucleus. *bioRxiv*, 2020.2008.2025.267435, doi:10.1101/2020.08.25.267435 (2020).

1707 47 Deniz, O. *et al.* Endogenous retroviruses are a source of enhancers with oncogenic
1708 potential in acute myeloid leukaemia. *Nature communications* **11**, 3506,
1709 doi:10.1038/s41467-020-17206-4 (2020).

1710 48 Geis, F. K. & Goff, S. P. Silencing and Transcriptional Regulation of Endogenous
1711 Retroviruses: An Overview. *Viruses* **12**, doi:10.3390/v12080884 (2020).

1712 49 Li, W. *et al.* Human endogenous retrovirus-K contributes to motor neuron disease. *Sci*
1713 *Transl Med* **7**, 307ra153, doi:10.1126/scitranslmed.aac8201 (2015).

1714 50 Karlsson, H. *et al.* Retroviral RNA identified in the cerebrospinal fluids and brains of
1715 individuals with schizophrenia. *Proceedings of the National Academy of Sciences of the*
1716 *United States of America* **98**, 4634-4639, doi:10.1073/pnas.061021998 (2001).

1717 51 Jonsson, M. E. *et al.* Activation of endogenous retroviruses during brain development
1718 causes an inflammatory response. *The EMBO journal* **40**, e106423,
1719 doi:10.15252/embj.2020106423 (2021).

1720 52 Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated
1721 proteomic-sample processing applied to copy-number estimation in eukaryotic cells.
1722 *Nature methods* **11**, 319-324, doi:10.1038/nmeth.2834 (2014).

1723 53 Ni, Y. *et al.* Mutations in NDUFS1 Cause Metabolic Reprogramming and Disruption of
1724 the Electron Transfer. *Cells* **8**, doi:10.3390/cells8101149 (2019).

1725 54 Martens, L. *et al.* PRIDE: the proteomics identifications database. *Proteomics* **5**, 3537-
1726 3545, doi:10.1002/pmic.200401303 (2005).

1727 55 Orlando, D. A. *et al.* Quantitative ChIP-Seq normalization reveals global modulation of
1728 the epigenome. *Cell reports* **9**, 1163-1170, doi:10.1016/j.celrep.2014.10.018 (2014).

1729 56 Rao, S. S. *et al.* A 3D map of the human genome at kilobase resolution reveals principles
1730 of chromatin looping. *Cell* **159**, 1665-1680, doi:10.1016/j.cell.2014.11.021 (2014).

1731 57 Basu, S. *et al.* Unblending of Transcriptional Condensates in Human Repeat Expansion
1732 Disease. *Cell* **181**, 1062-1079 e1030, doi:10.1016/j.cell.2020.04.018 (2020).

1733 58 Nakagata, N. Cryopreservation of mouse spermatozoa and in vitro fertilization. *Methods*
1734 *in molecular biology* **693**, 57-73, doi:10.1007/978-1-60761-974-1_4 (2011).

1735 59 Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
1736 *2011* **17**, 3, doi:10.14806/ej.17.1.200 (2011).

1737 60 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21,
1738 doi:10.1093/bioinformatics/bts635 (2013).

1739 61 Pertea, M. *et al.* StringTie enables improved reconstruction of a transcriptome from
1740 RNA-seq reads. *Nature biotechnology* **33**, 290-295, doi:10.1038/nbt.3122 (2015).

1741 62 Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data
1742 processing and web-based tools. *Nucleic acids research* **41**, D590-596,
1743 doi:10.1093/nar/gks1219 (2013).

1744 63 Neumann, T. *et al.* Quantification of experimentally induced nucleotide conversions in
1745 high-throughput sequencing datasets. *BMC Bioinformatics* **20**, 258, doi:10.1186/s12859-
1746 019-2849-7 (2019).

1747 64 Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-
1748 throughput sequencing data. *Bioinformatics* **31**, 166-169,
1749 doi:10.1093/bioinformatics/btu638 (2015).

1750 65 Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible
1751 platform for exploring deep-sequencing data. *Nucleic acids research* **42**, W187-191,
1752 doi:10.1093/nar/gku365 (2014).

1753 66 Ji, X. *et al.* Chromatin proteomic profiling reveals novel proteins associated with histone-
1754 marked genomic regions. *Proceedings of the National Academy of Sciences of the United*
1755 *States of America* **112**, 3841-3846, doi:10.1073/pnas.1502971112 (2015).

1756 67 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler
1757 transform. *Bioinformatics* **25**, 1754-1760, doi:10.1093/bioinformatics/btp324 (2009).

1758 68 McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for
1759 analyzing next-generation DNA sequencing data. *Genome research* **20**, 1297-1303,
1760 doi:10.1101/gr.107524.110 (2010).

1761 69 Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome biology* **9**, R137,
1762 doi:10.1186/gb-2008-9-9-r137 (2008).

1763 70 Kharchenko, P. V., Tolstorukov, M. Y. & Park, P. J. Design and analysis of ChIP-seq
1764 experiments for DNA-binding proteins. *Nature biotechnology* **26**, 1351-1359,
1765 doi:10.1038/nbt.1508 (2008).

1766 71 Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934-
1767 947, doi:10.1016/j.cell.2013.09.053 (2013).

1768 72 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
1769 for RNA-seq data with DESeq2. *Genome biology* **15**, 550, doi:10.1186/s13059-014-0550-
1770 8 (2014).

1771 73 Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime
1772 cis-regulatory elements required for macrophage and B cell identities. *Molecular cell* **38**,
1773 576-589, doi:10.1016/j.molcel.2010.05.004 (2010).

1774 74 Durinck, S., Spellman, P. T., Birney, E. & Huber, W. Mapping identifiers for the
1775 integration of genomic datasets with the R/Bioconductor package biomaRt. *Nature*
1776 *protocols* **4**, 1184-1191, doi:10.1038/nprot.2009.97 (2009).

1777 75 Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis.
1778 *bioRxiv*, 060012, doi:10.1101/060012 (2019).

1779 76 Jurka, J. *et al.* Repbase Update, a database of eukaryotic repetitive elements. *Cytogenet*
1780 *Genome Res* **110**, 462-467, doi:10.1159/000084979 (2005).

1781 77 Stocking, C. & Kozak, C. A. Murine endogenous retroviruses. *Cell Mol Life Sci* **65**,
1782 3383-3398, doi:10.1007/s00018-008-8497-0 (2008).

1783 78 Crichton, J. H., Dunican, D. S., Maclellan, M., Meehan, R. R. & Adams, I. R. Defending
1784 the genome from the enemy within: mechanisms of retrotransposon suppression in the
1785 mouse germline. *Cell Mol Life Sci* **71**, 1581-1605, doi:10.1007/s00018-013-1468-0
1786 (2014).

1787 79 Pockrandt, C., Alzamel, M., Iliopoulos, C. S. & Reinert, K. GenMap: ultra-fast
1788 computation of genome mappability. *Bioinformatics* **36**, 3687-3692,
1789 doi:10.1093/bioinformatics/btaa222 (2020).

1790 80 Lawrence, M., Gentleman, R. & Carey, V. rtracklayer: an R package for interfacing with
1791 genome browsers. *Bioinformatics* **25**, 1841-1842, doi:10.1093/bioinformatics/btp328
1792 (2009).

1793 81 Gu, Z., Eils, R., Schlesner, M. & Ishaque, N. EnrichedHeatmap: an R/Bioconductor
1794 package for comprehensive visualization of genomic signal associations. *BMC genomics*
1795 **19**, 234, doi:10.1186/s12864-018-4625-x (2018).

1796 82 Flyamer, I. M., Illingworth, R. S. & Bickmore, W. A. Coolpup.py: versatile pile-up
1797 analysis of Hi-C data. *Bioinformatics* **36**, 2980-2985, doi:10.1093/bioinformatics/btaa073
1798 (2020).

1799 83 McLeay, R. C. & Bailey, T. L. Motif Enrichment Analysis: a unified framework and an
1800 evaluation on ChIP data. *BMC Bioinformatics* **11**, 165, doi:10.1186/1471-2105-11-165
1801 (2010).

1802 84 Chan, M. M. *et al.* Molecular recording of mammalian embryogenesis. *Nature* **570**, 77-
1803 82, doi:10.1038/s41586-019-1184-5 (2019).

1804 85 Krueger, F. & Andrews, S. R. SNPsplit: Allele-specific splitting of alignments between
1805 genomes with known SNP genotypes. *F1000Res* **5**, 1479,
1806 doi:10.12688/f1000research.9037.2 (2016).

1807 86 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902
1808 e1821, doi:10.1016/j.cell.2019.05.031 (2019).

1809 87 La Manno, G. *et al.* RNA velocity of single cells. *Nature* **560**, 494-498,
1810 doi:10.1038/s41586-018-0414-6 (2018).

1811 88 Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression
1812 data analysis. *Genome biology* **19**, 15, doi:10.1186/s13059-017-1382-0 (2018).

1813

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TableS1NGA58214Hniesz210911.xlsx](#)
- [TableS2NGA58214Hniesz210911.xlsx](#)
- [TableS3NGA58214Hniesz210911.xlsx](#)
- [TableS4NGA58214Hniesz210911.xlsx](#)
- [TableS5NGA58214Hniesz210911.xlsx](#)
- [TableS6NGA58214Hniesz210911.xlsx](#)